Mechanisms of GTP-depletion induced apoptosis in HIT-T15 insulin-secreting cells by HUO JIANXIN
MECHANISMS OF GTP-DEPLETION INDUCED APOPTOSIS 
IN HIT-T15 INSULIN SECRETING CELLS 
HUO JIANXIN 
(B. Sc., NAN KAI UNIV.) 
A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
NATIONAL UNIVERSITY MEDICAL INSTITUTES 





My great appreciation goes to my supervisor, Dr. Li Guodong, for his invaluable 
supervision and encouragement throughout the course of this research project. 
I thank all examiners (Dr. Marie-Veronique Clement at Dept of Biochemistry, NUS; 
Prof. Anjan Kowluru with Wayne State University, Detroit, MI, USA; and Prof. 
Noel G. Morgan at Peninsula Medical School, Plymouth, UK) for their critical 
reading of the thesis. 
I am deeply indebted to my parents and my wife for their full-hearted support and 
understanding throughout my studies. 
I am very grateful to all colleagues in my laboratory for their excellent technical 
assistance, encouragement and friendship. 
I thank the National University of Singapore for the award of a research 
scholarship which gave me the opportunity to pursue my Ph. D studies. 
Finally, I would like to say that my time as a post-graduate student at the NUS is a 
memorable and fulfilling stage in my life. 
 
Table of Contents 
  ii
Table of Contents 
ACKNOWLEDGMENTS............................................................................................ I 
TABLE OF CONTENTS ............................................................................................II 
TABLES AND FIGURES ......................................................................................... VI 
SUMMARY ............................................................................................................. VIII 
ABBREVIATIONS.................................................................................................... XI 
PUBLICATIONS .................................................................................................... XIV 
JOURNAL ARTICLES: ................................................................................................ XIV 
CONFERENCE PAPERS: ............................................................................................. XIV 
CHAPTER 1 INTRODUCTION.................................................................................1 
1.1. CHARACTERISTICS OF APOPTOSIS..........................................................................2 
1.1.1. Overview of apoptosis ..............................................................................................2 
1.1.2. Morphological and molecular changes of cellular organelles in apoptosis ............3 
1.2. TISSUE TRANSGLUTAMINASE AND APOPTOSIS .......................................................6 
1.2.1. Transglutaminase family ..........................................................................................6 
1.2.2. Tissue transglutaminase (tTG) .................................................................................8 
1.2.3. Role of tTG in apoptosis...........................................................................................9 
1.3. CASPASES AND APOPTOSIS ..................................................................................10 
1.3.1. Caspase family .......................................................................................................11 
1.3.2. Caspase activation .................................................................................................12 
1.3.3. Adaptor proteins for caspase activation ................................................................12 
1.3.4. Apoptosis signaling ................................................................................................13 
Table of Contents 
  iii
1.3.5. Caspase substrates .................................................................................................14 
1.3.6. Caspase inhibitors..................................................................................................15 
1.4. CELL CYCLE AND APOPTOSIS...............................................................................15 
1.4.1. Cell cycle regulation: co-ordination of cyclins, CDKs and CKIs ..........................15 
1.4.2. Cell cycle and apoptosis.........................................................................................17 
1.4.3. p21WAF1/CIP1, p27KIP1 and cell cycle .........................................................................17 
1.5. GTP DEPLETION AND APOPTOSIS.........................................................................18 
1.5.1. GTP biosynthesis and IMP dehydrogenase (IMPDH) ...........................................18 
1.5.2. IMPDH inhibitors ..................................................................................................21 
1.5.3. Mycophenolic acid (MPA) .....................................................................................22 
1.5.4. IMPDH in β-cells ...................................................................................................23 
1.5.5. MPA and apoptosis of insulin secreting cells ........................................................23 
1.6. AIM OF THIS STUDY.............................................................................................25 
1.6.1. Does tTG participate in MPA induced β-cell apoptosis?.......................................25 
1.6.2. Is any caspase involved in MPA induced β-cell apoptosis?...................................26 
1.6.3. Is any cell cycle regulator(s) important for MPA-induced β-cell apoptosis? ........27 
CHAPTER 2 MATERIALS AND METHODS........................................................29 
2.1. MATERIALS.........................................................................................................30 
2.2. METHODS............................................................................................................35 
2.2.1. Cell culture and storage.........................................................................................35 
2.2.2. Detection of apoptosis by MTS test and DNA content determination ....................36 
2.2.3. Flow cytometric analysis for DNA fragmentation and cell cycle...........................38 
2.2.4. Protein concentration assay...................................................................................39 
2.2.5. Assay of in situ tTG activity....................................................................................40 
2.2.6. Caspase activity measurement ...............................................................................41 
2.2.7. Isolation of mitochondria-enriched and cytosolic fractions ..................................42 
2.2.8. Examination of cell morphology ............................................................................43 
Table of Contents 
  iv
2.2.9. Immunoprecipitation of RAIDD and caspase-2 .....................................................43 
2.2.10. Western blotting of tTG, caspase-2, RAIDD, cytochrome c, p53, p21WAF1/CIP1 and 
p27KIP1....................................................................................................................44 
2.2.11. Determination of lactate dehydrogenase (LDH) release .....................................45 
2.2.12. Statistical analysis................................................................................................46 
CHAPTER 3 RESULTS.............................................................................................47 
3.1. ROLE OF TTG IN GTP DEPLETION INDUCED APOPTOSIS OF INSULIN-SECRETING 
CELLS ..................................................................................................................48 
3.1.1. Increase of in situ tTG activity and induction of apoptosis by MPA in HIT cells ..48 
3.1.2. Effects of tTG inhibitors on tTG activity and apoptosis during MPA treatment....50 
3.1.3. Effects of caspase inhibitor on tTG activity in GTP depletion...............................52 
3.1.4. tTG activity and cell morphology...........................................................................53 
3.1.5. Section summary ....................................................................................................56 
3.2. IMPORTANCE OF ACTIVATION OF CASPASES FOR THE APOPTOSIS INDUCED BY 
GTP-DEPLETION IN INSULIN-SECRETING CELLS...................................................57 
3.2.1. Induction of apoptosis by GTP depletion with MPA treatment..............................57 
3.2.2. Activation of caspases and release of cytochrome c by MPA treatment ................59 
3.2.3. Blockade of MPA-induced apoptosis by caspase inhibitors...................................62 
3.2.4. Section summary ....................................................................................................65 
3.3. ROLE OF CELL CYCLE REGULATORS IN THE ACTIVATION OF CASPASES AND 
INDUCTION OF APOPTOSIS IN Β-CELLS DUE TO GTP-DEPLETION ..........................67 
3.3.1. Increment of p21WAF1/CIP1  by MPA treatment .........................................................67 
3.3.2. Reduction of p53 and p27KIP1 during MPA treatment ............................................68 
3.3.3. Induction of p21WAF1/CIP1 and caspase activation ...................................................71 
3.3.4. Section summary ....................................................................................................74 
CHAPTER 4  DISCUSSION .....................................................................................75 
Table of Contents 
  v
4.1. THE ROLE OF TTG IN APOPTOSIS INDUCED BY GTP DEPLETION ..........................76 
4.1.1. Evidence for association of tTG expression/activation with apoptosis..................76 
4.1.2. Increase of tTG activity by GTP depletion per se but not by its up-expression in 
HIT cells ................................................................................................................77 
4.1.3. tTG activation is an epiphenomenon during MPA-induced apoptosis of HIT cells79 
4.1.4. Role of tTG in GTP depletion-induced apoptosis of HIT cells...............................81 
4.1.5. Relationship between tTG and caspases ................................................................82 
4.2. CASPASE ACTIVATION IN β-CELL APOPTOSIS INDUCED BY GTP DEPLETION ........84 
4.2.1. Activation of multiple caspases in MPA-induced apoptosis of HIT cells...............84 
4.2.2. Caspase-2 activation is prior to cytochrome c release and caspase-9 activation .84 
4.2.3. Activation of caspase-2 mediates β-cell apoptosis due to GN-depletion ...............85 
4.2.4. Possible mechanism for caspase-2 activation in β-cell by GN-depletion ..............86 
4.2.5. Involvement of caspases in β-cell death caused by harsh challenges ....................87 
4.3. ROLE OF CELL CYCLE REGULATORS IN β-CELL APOPTOSIS INDUCED BY GTP 
DEPLETION...........................................................................................................89 
4.3.1. Close relationship between p21WAF1/CIP1 and caspase activation in β-cells............89 
4.3.2 Activation of caspase(s) and p21WAF1/CIP1 degradation ...........................................91 
4.3.3. Induction of p53-independent p21WAF1/CIP1 increment by MPA ..............................91 
4.3.4. p27KIP1 degradation by MPA treatment ..................................................................92 
4.3.5. Cell cycle and apoptosis in β-cells.........................................................................93 
4.4. FUTURE WORK ....................................................................................................94 
REFERENCES............................................................................................................97 
 
Tables and Figures 
  vi
Tables and Figures 
Figure 1. Cell death classification.................................................................................................2 
Table 1. Transglutaminase family.................................................................................................8 
Table 2. Caspase family..............................................................................................................12 
Figure 2. Apoptosis signalling pathways. ...................................................................................14 
Figure 3. Cell cycle regulators. ...................................................................................................16 
Figure 4.Schematic representation of purine nucleotides de novo and salvage pathways ..........19 
Figure 5. Structure of mycophenolic acid...................................................................................23 
Figure 6. Prolonged MPA treatment induces apoptotic changes in HIT cells ............................25 
Table 3. Selected conditions of Western blotting on different proteins in this study. ................45 
Figure 7. Induction of apoptosis of HIT cells by MPA treatment in dose-dependent manner. ..48 
Figure 8. Increase of in situ tTG activity by GTP-depletion after MPA treatment in a dose-
dependent manner .....................................................................................................49 
Figure 9. Prevention of MPA-promoted increase of in situ tTG activity and induction of cell 
death by the provision of guanosine but not adenosine. ...........................................50 
Figure 10. Decrease of tTG expression at protein level after 48-h MPA treatment. ..................50 
Figure 11. Partial suppression of MPA-enhanced tTG activity but failure of prevention of 
MPA-induced apoptosis by two tTG inhibitors ........................................................51 
Figure 12. Significant suppression of MPA-enhanced tTG activity by EGTA without preventing 
MPA-induced apoptosis............................................................................................52 
Table 4. Analysis of MPA-induced subdiploidy apoptosis by flow cytometry. .........................52 
Figure 13. Prevention by a pan-caspase inhibitor of apoptosis but not the increased tTG activity 
induced by MPA. ......................................................................................................53 
Tables and Figures 
  vii
Figure 14. Failure of complete prevention of MPA-induced morphological alterations by a pan-
caspase inhibitor........................................................................................................55 
Figure 15. LDH release from HIT cells after MPA treatment under various conditions............56 
Figure 16.Time-course of cell death induced by MPA treatment ...............................................58 
Table 5. Effects of MPA treatment on cell cycle of HIT cells....................................................58 
Figure 17. Activity of caspases in HIT cells during MPA treatment..........................................60 
Figure 18 Cleavage of caspase-2 by MPA treatment and interaction of RAIDD with caspase-2.61 
Figure 19. Release of cytochrome c from mitochondria into cytosol during MPA treatment. ...61 
Figure 20. Blockade of GN-depletion induced cell death by a pan-caspase inhibitor. ...............64 
Figure 21. Blockade of GN-depletion induced cell death by a specific caspase-2 inhibitor. .....65 
Figure 22. Partial prevention by a caspase-3 inhibitor of reduction of DNA content induced by 
GN; comparison to absence of effect on cell viability. .............................................65 
Figure 23. Close correlation of time-response between the increment of p21WAF1/CIP1 mass 
and activation of caspases in MPA treated HIT-T15 cells........................................68 
Figure 24. Reduction of p53 protein by MPA treatment ............................................................69 
Figure 25. Decrement of p27KIP1 by exposure to MPA in a time- and dose-dependent manner.70 
Figure 26. No restorative effect by caspase inhibitors on MPA-induced reduction of p53 and 
p27KIP1. ...................................................................................................................71 
Figure 27. Induction p21WAF1/CIP1 and activation of caspases by mimosine treatment. .......72 
Figure 28. Blockage by a caspase inhibitor of mimosine-induced arrest of cell cycle and 
induction of apoptotic cell death...............................................................................73 
Figure 29. Enhancement of MPA-induced p21WAF1/CIP1 increment by caspase inhibitors ...74 





Mycophenolic acid (MPA), selectively depletes intracellular guanine nucleotides by 
inhibition of IMP dehydrogenase, and induces apoptosis of islet β-cells. This study 
investigated the underlying mechanisms of this scenario. 
As a calcium-dependent and GTP-modulated enzyme, tissue transglutaminase (tTG) 
may be involved in apoptosis by cross-linking intracellular proteins. Our results 
showed that MPA increased tTG activity (but not protein levels) in a dose- and time-
dependent manner in close relationship with the induction of apoptosis. Co-exposure 
to either monodansylcadaverine or putrescine (tTG inhibitors) reduced MPA-enhanced 
tTG activity significantly, but failed to prevent the apoptosis. Similarly, lowering free 
Ca2+
 
concentrations by EGTA also did not improve cell viability, although most of the 
enhanced tTG activity was blocked. Importantly, a pan-caspase inhibitor, which 
entirely prevented apoptosis induced by MPA, did not block the enhancing effect of 
MPA on tTG activity, indicating that MPA may induce apoptosis and activate tTG 
independently. However, tTG inhibition was able to partially reverse the accompanied 
morphological changes. These findings suggest that tTG activation may be restricted 
to some terminal morphological changes, but may not play a critical role in the 
initiation of this kind of apoptosis. 
This study also investigated the possible involvement of caspase(s) in GTP-depletion-
induced apoptosis. MPA reduced progression of cell cycle from G1 phase into S and 
G2/M phases and induced apoptosis. The latter event was accompanied by a marked 
increase of caspase-2 activity and moderate activation of caspase-9 and -3. However, 
only caspase-2 activation preceded the appearance of apparent apoptosis. There was 
no change in activity of caspase-1, -4, -5, -6 and -8. Release of the mitochondrial 
Summary 
  ix
protein cytochrome c into cytosol was also observed at a late stage. Importantly, co-
treatment of cells with a pan-caspase inhibitor blocked MPA-induced apoptosis in a 
dose-dependent manner. Moreover, a specific caspase-2 inhibitor, but not a caspase-3 
inhibitor, was also capable of restoring cell viability. Interestingly, activation of 
caspase-2 appeared prior to caspase-3 activation. These results indicate that while 
activation of multiple caspases is involved in the execution of MPA-induced apoptosis 
of β-cells, caspase-2 plays the major role in the initiation of this kind of programmed 
cell death. These findings revealed a novel, caspase-2 mediated form of apoptosis that 
may be consequent to impaired mitogenesis. 
Furthermore, the possible relationship between arrest of cell growth and activation of 
caspases during MPA-induced apoptosis of β-cells was examined, focusing on three 
important signalling molecules (p53, p21WAF1/CIP1 and p27KIP1) which regulate cell 
cycle. p21WAF1/CIP1 was significantly increased following MPA treatment. This 
phenomenon was closely correlated with the time-course of caspase activation under 
the same conditions. Interestingly, MPA-induced p21WAF1/CIP1 was not mediated by 
p53, since p53 mass was gradually reduced during MPA treatment. In addition, the 
increment of p21WAF1/CIP1 by MPA was further enhanced in the presence of a pan-
caspase inhibitor, suggesting that an increase of p21WAF1/CIP1 may occur prior to 
caspase activation. This notion of association of p21WAF1/CIP1 accumulation with 
caspase activation and apoptosis was substantiated by using mimosine, a selective 
p21WAF1/CIP1-inducer independent of p53. Mimosine, like MPA, also increased 
p21WAF1/CIP1, promoted apoptosis and simultaneously increased activity of several 
caspases. In contrast to p21WAF1/CIP1, a reduction in p27KIP1 occurred in MPA-treated 
cells. These results indicate that p21WAF1/CIP1 may act as an upstream signal by 
Summary 
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blocking mitogenesis to activate caspases and in turn induce apoptosis during 
sustained GTP-depletion.  
In conclusion, this work has demonstrated that GTP depletion-induced apoptosis of β-
cells is mediated by activation of mainly caspase-2. In this process, p21WAF1/CIP1 might 
be an important linking molecule between inhibition of mitogenesis and activation of 
caspases. However, tTG seems not to be a critical player in this scenario, though it 
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1.1. Characteristics of apoptosis 
1.1.1. Overview of apoptosis 
Mechanisms that regulate cell death are essential for normal development and 
maintenance of homeostasis of the body. Individual cells may die either by accident or 
by design. Accidental cell death may be induced by lethal stimuli such as trauma or 
infection, leading to necrosis. Necrotic cells are characteristically swollen rather than 
shrunk. The loss of electrolytes and water balance following damage to the plasma 
membrane cause acidosis and osmotic shock, which distend cellular organelles such as 
mitochondria, endoplasmic reticulum (ER) and lysosomes. Eventually, inflammatory 
debris are released. Contrary to necrosis, death by design, which is termed 
programmed cell death (PCD), is a coordinated and regulated process (Lockshin and 
Williams, 1964; Lockshin, 1969, 1971). PCD includes apoptotic (Type 1) and non-
apoptotic types; the latter can be further classed into vacuolar (Type 2), atrophic (Type 
3), as well as differentiation to death (Fig. 1) (Bowen et al., 1998). Apoptotic cells are 














Differentiation to death  
Fig. 1. Cell death classification 
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Apoptosis, a physiologically regulated destruction of supernumerary, misplaced or 
damaged cells with high specificity and efficiency, is critical for the normal 
development and function of multicellular organisms. Apoptosis is implemented 
through the activation of an evolutionarily conserved molecular programme intrinsic 
to all metazoan cells. Dysfunctions in the regulation or execution of apoptosis can 
contribute to a wide range of developmental abnormalities and diseases, including 
cancer (failure to undergo apoptosis), autoimmunity and degenerative disorders 
(excessive apoptosis) (Meier et al., 2000; Hengartner, 2000; Strasser et al., 2000). 
1.1.2. Morphological and molecular changes of cellular organelles in apoptosis 
As a physiological process for eliminating cells, apoptosis is distinct from necrosis 
which causes cell break-up and release of inflammatory debris. Apoptotic cells display 
some specific morphological changes, e.g. plasma membrane blebbing, nuclear 
condensation, and DNA fragmentation at nucleosomal intervals. These changes were 
first characterised by Kerr and colleagues in 1972 (Kerr et al., 1972). The more 
detailed features of apoptosis, including morphological changes and related molecular 
alterations, were defined in the following decades. Different subcellular 
compartments, such as cell membrane, cytoplasm, nucleus, mitochondria, ER, and 
Golgi apparatus, are implicated in apoptosis of diverse cells induced by a broad range 
of death stimuli. 
1.1.2.1. Cytoplasm, nucleus and cell membrane 
Apoptosis results in characteristic morphological features that are mostly evident in 
the nucleus, such as peripheral chromatin clumping, chromatin condensation, nuclear 
shrinkage, and the formation of apoptotic bodies. Cytoplasmic changes include 
cytoskeletal disruption, cytoplasmic shrinkage and condensation. These alterations are 
the results of biochemical and molecular changes, such as inter-nucleosomal DNA 
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cleavage (DNA ladder formation), RNA cleavage, post-translational modifications of 
nuclear proteins, and proteolysis of several polypeptides residing in the nucleus 
(Martelli et al., 2001). The changes in cell membrane during apoptosis include the 
externalization of phosphatidylserine (a phospholipid normally confined to the 
cytoplasmic face of the plasma membrane) to the outer membrane during apoptosis, 
and membrane blebbing which leads to the formation of cell membrane-bound 
vesicles or apoptotic bodies (Blankenberg et al., 2000).  
1.1.2.2. Mitochondria 
In contrast to nuclear shrinkage in apoptosis, 'swelling of mitochondria' may occur 
during the apoptotic processes. Enlargement of mitochondria induced by various 
apoptotic stimuli are classified into two categories: the swelling and the formation of 
megamitochondria (Matsuyama and Reed, 2000; Wakabayashi and Karbowski, 2001). 
Importantly, mitochondria play a critical role in the signaling of apoptosis in response 
to various stimuli. A series of events may occur, including: (1) changes in electron 
transport; (2) loss of mitochondrial transmembrane potential; (3) altered cellular 
oxidation-reduction; (4) participation of pro- and anti-apoptotic proteins of Bax/Bcl-2 
family; and most importantly, (5) the release of caspase activators [such as 
cytochrome c, AIF (apoptosis-inducing factor) and SMAC (second mitochondria-
derived activator of caspase)/Diablo (direct IAP binding protein with low pI)], and 
even caspases from the intermembrane space into the cytosol (Vander Heiden et al., 
1997; Green and Reed, 1998; Shi, 2001). The exact mechanism by which these 
proteins release from mitochondria remains enigmatic. Eventually, the released 
cytochrome c and AIF will initiate a caspase-9 mediated apoptotic program (to be 
described in detail later) (Yang et al., 1997; Kluck et al., 1997; Susin et al., 1999b).  
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1.1.2.3. Endoplasmic Reticulum 
ER is also a major place of integration of pro-apoptotic signaling or damage 
awareness. ER senses local stress through chaperones, Ca2+-binding proteins and Ca2+ 
release channels, which might transmit ER’s Ca2+ responses to mitochondria. ER also 
contains several Bcl-2-binding proteins, which may exert part of its cytoprotective 
effects within the ER (Ferri and Kroemer, 2001). Furthermore, ER is involved in 
activation of certain caspases. Nakagawa et al discovered that caspase-12 is localized 
in ER and activated by ER stress (such as disruption of ER calcium homeostasis or 
accumulation of excess proteins in ER), but not by membrane- or mitochondrial-
targeted apoptotic signals (Nakagawa et al., 2000). Rao et al showed that ER stress 
also induces the expression of caspase-12, leads to the translocation of cytosolic 
caspase-7 to the ER surface, and mediates caspase-12 activation (Rao et al., 2001). 
Recently, Breckenridge et al reported an additional caspase-8 activation pathway in 
which procaspase-8L (the procaspase-8 isoform) is preferentially recruited by the 
complex of BAP31 (an integral protein of ER membrane and a substrate of caspase-8) 
at ER (Breckenridge et al., 2002).  
1.1.2.4. Golgi apparatus 
Fragmentation of Golgi apparatus was found as an apoptotic morphological change in 
a report by Dinsdale et al (Dinsdale et al., 1999). More interestingly, it was 
demonstrated that caspase-2 is localized in Golgi complex, where it cleaves golgin 160 
which is a Golgi-localized macromolecule (Mancini et al., 2000). Recently, Lane et al 
found that GRASP65 (Golgi reassembly and stacking protein of 65 kDa), an 
important structural component required for maintenance of Golgi apparatus integrity, 
is cleaved specifically by caspase-3 (Lane et al., 2002). These results indicate that 
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Golgi complex may sense and integrate unique local changes and transduce pro-
apoptotic signals through certain caspases (Mancini et al., 2000). 
Taken all observations in this section together, we can envisage that apoptosis is a 
process which may not be restricted to a particular component of the cell. Various 
stimuli attack diverse cellular organelles and activate multiple apoptotic pathways 
which converge to a common machinery (e.g. caspase activation; being described 
later) of cell death. 
1.2. Tissue transglutaminase and apoptosis 
Some studies suggested that tissue transglutaminase (tTG) might participate in the 
induction of apoptosis (Fesus and Thomazy, 1988; Fesus, 1998; Melino and 
Piacentini, 1998; Autuori et al., 1998). It has been reported that tTG selectively 
accumulates and its activity is markedly increased in cells undergoing apoptosis 
(Fesus and Thomazy, 1988; Fesus, 1998; Melino and Piacentini, 1998; Autuori et al., 
1998). However, its exact role in apoptosis, albeit extensively studied in recent years 
(Fesus and Thomazy, 1988; Melino et al., 1997; Melino and Piacentini, 1998; Autuori 
et al., 1998), is still not clear. 
1.2.1. Transglutaminase family 
Transglutaminases (Tgases, EC 2.3.2.13) are a group of intracellular and extracellular 
thiol- and Ca2+-dependent acyl transferases that catalyze the formation of an amide 
bond [irreversible ε- (γ-glutamyl) lysine or N, N-bis (γ-glutamyl) polyamine bonds] 
between γ-carboxamide groups of peptide-bound glutamine residues and the primary 
amino groups in various compounds, such as the ε-amino groups of lysine residues in 
certain proteins or the amino groups from polyamines (Fesus and Thomazy, 1988; 
Fesus, 1998; Melino and Piacentini, 1998; Folk et al., 1980; Folk, 1980; Fesus et al., 
 Chapter 1 Introduction 
  7
1985; Piacentini et al., 1988). Generally, this kind of covalent isopeptide crosslink 
stabilizes tissues since it is stable and resistant to proteolysis, thereby increasing the 
resistance of tissue to chemical, enzymatic, and mechanical disruption (Greenberg et 
al., 1991).  
At least seven different transglutaminases have been characterized and each of them 
has specific functions (Table 1) (Folk, 1980; Fesus and Thomazy, 1988; Aeschlimann 
and Paulsson, 1994; Aeschlimann et al., 1998).  
Table 1. Transglutaminase family 
Type  Abbreviation M. W. (kDa) Location Function 
Keratinocyte Tgase 1, TGK 92 Keratinocytes 
Terminal differentiation events 
of keratinocytes (Kim et al., 
1993; Kim et al., 1995) 




the cytosol of 
many cells and 
tissues  
1. Signalling for GTP-binding 
protein coupled receptors 
(Nakaoka et al., 1994; Feng et 
al., 1996; Feng et al., 1999) 
2. Multiple-function in post-
translational modification of 
proteins (Piacentini et al., 2000) 
3. Apoptosis (Melino and 
Piacentini, 1998; Autuori et al., 
1998; Piacentini et al., 2000) 
4. Differentiation (Hand et al., 
1993) 
Epidermal Tgase 3, TGE 77 Epidermis 
Cross-link structural proteins 
forming the cornified cell 
envelope (Steinert and Marekov, 
1995; Rice and Green, 1977) 





(Aeschlimann and Paulsson, 
1994; Lorand and Conrad, 1984) 
Coagulation 
factor XIIIa  80 Blood plasma 
Cross-link formation in fibrin 
(Lorand and Conrad, 1984; 
Aeschlimann and Paulsson, 
1994) 
Band 4.2 protein   Erythrocyte membrane 
Structural component of the 
cytoskeleton (Cohen et al., 1993) 
Novel Tgase X, TGx 81 Keratinocytes 
Formation of the cornified 
envelope (Aeschlimann et al., 
1998) 
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1.2.2. Tissue transglutaminase (tTG) 
tTG (EC 2.3.2.13, or Tgase 2, TGC) is a cytosolic protein with molecular weight of 
~80 kDa (slightly different among species). Interestingly, tTG is a protein of dual 
function. On one hand, it possesses properties of a GTP-binding protein/GTPase (thus 
is also called Gh) which transduces the stimulation of certain receptors to 
phospholipase Cδ in some type of cells (Nakaoka et al., 1994; Feng et al., 1996; Im et 
al., 1997; Vezza et al., 1999). On the other hand, this protein has transamidating 
activity which causes cross-linking of specific substrates in cytosol and nucleus 
(Cooper et al., 2000). tTG is identified in pancreatic islet cells, endothelial and smooth 
muscle cells, heart muscle, medullary interstitial and mesangial cells of kidney (Fesus 
and Thomazy, 1988; Dvorcakova et al., 2002). It can also be induced under a variety 
of conditions in many other types of cells, suggesting its multiple functions (Piacentini 
et al., 2000).  
Importantly, tTG activity is mainly regulated by intracellular levels of both Ca2+ and 
GTP; an increase of the former or a reduction of the latter stimulates its 
transglutaminase activity (Smethurst and Griffin, 1996; Melino and Piacentini, 1998; 
Zhang et al., 1998). Therefore, tTG activity may be suppressed in the presence of 
normal ambient GTP concentrations (mM range). Other factors such as redox 
potentials (glutathione disulfide and S-nitrosylation), polyamines and 
sphingosylphosphocholine may also modulate tTG activity (Melino and Piacentini, 
1998). 
The presence of transglutaminase activity in islets was firstly reported in 1983 (Gomis 
et al., 1983) and a number of studies attempted to understand its potential role in 
insulin secretion (Sener et al, 1984; Sener et al, 1985; Bungay et al, 1984; Gomis et al, 
1986). It has been found that tTG may be involved in the membrane-mediated events 
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required for glucose-stimulated insulin release from beta-cells, since tTG inhibitors 
significantly inhibited glucose-stimulated insulin release from isolated rat islets 
(Bungay et al., 1986). Furthermore, a recent study reported that knockout of tTG in 
mice resulted in the loss of tTG and impaired glucose-stimulated insulin secretion 
leading to the development of type-2 diabetes (Bernassola et al., 2002). Therefore, tTG 
appears important for the maintainence of islet beta-cell function and insulin secretion 
(Dvorcakova et al., 2002).  
1.2.3. Role of tTG in apoptosis  
tTG is capable of cross-linking proteins and may prevent leakage of intracellular 
components, thereby reducing inflammation and autoimmunity. Some studies 
suggested that tTG might also participate in the induction of apoptosis (Fesus and 
Thomazy, 1988; Melino and Piacentini, 1998; Autuori et al., 1998; Fesus, 1998). 
Therefore, the role of tTG in the regulation of apoptosis is extensively studied in 
recent years. 
Several in vivo and in vitro experimental systems have demonstrated a direct 
relationship between tTG (in both expression and activity) and apoptosis. It has been 
reported that tTG is selectively accumulated and its activity is markedly increased in 
cells undergoing apoptosis (Fesus and Thomazy, 1988; Melino and Piacentini, 1998; 
Autuori et al., 1998; Fesus, 1998; Uray et al., 2001). In addition, transcription of tTG 
mRNA is a consequence of apoptosis induction (Ou et al., 2000; Uray et al., 2001) and 
overexpression of tTG in various cell types enhances their susceptibility to apoptosis 
(Piredda et al., 1999; Piacentini et al., 2002). Interestingly, many of tTG-targeted 
proteins are also the substrates of caspases (Autuori et al., 1998). Moreover, an 
inhibition of tTG expression in human leukemic U937 cells undergoing apoptosis 
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induced by all-trans- retinoic acid (RA) prevents their death, although this kind of 
apoptosis is caspase-independent (Oliverio et al., 1999).  
However, some recent studies indicated that tTG does not mediate apoptosis directly. 
In two reports (Nanda et al., 2001; De Laurenzi and Melino, 2001), the tTG(-/-) mice 
were viable and no major developmental abnormalities occurred. In addition, the 
induction of apoptosis in thymocytes and fibroblasts from these tTG(-/-) mice under a 
number of apoptotic conditions showed no significant difference from the wild-type 
cells. Furthermore, Boehm et al found that tTG possesses the ability of modifying 
retinoblastoma (Rb) via transamidation, thereby providing protection against 
apoptotic insults (Boehm et al., 2002). These results indicated that tTG has very 
complex roles in apoptosis. 
1.3. Caspases and apoptosis 
In Caenorhabditis elegans (C. elegans), the ICE (interleukin 1β-converting 
enzyme)/CED-3 (C. elegans cell death defective gene 3) encodes an aspartate-specific 
cysteine protease that is essential for apoptosis (Yuan et al., 1993; Xue et al., 1996). 
Subsequently, it was demonstrated that a large number of ICE/CED-3 related family 
of proteases also play key roles in mammalian apoptosis. For uniformity, these 
evolutionarily conserved cysteine proteases that cleave specific aspartic acid residues 
were termed caspases (Alnemri et al., 1996; Thornberry and Lazebnik, 1998). 
Caspases are not only responsible for the degradation of cellular substrates during the 
end stage of apoptosis, but also critical regulators of cell death initiation, playing 
critical roles in both the initiating and the executive phases of apoptosis. Different 
apoptotic signals converge on a common machinery of cell death by activating 
caspases (Strasser et al., 2000). 
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1.3.1. Caspase family 
Caspases are localized in various subcellular compartments. At least 14 members 
(Table 2) have been identified. Based on the presence of a large prodomain at their N-
terminal region and the substrate specificity (Strasser et al., 2000), caspases can be 
classed into two groups possessing different functions; large prodomain caspases 
(initiator) receiving apoptotic signals function as upstream signal transducers (e.g. 
caspase-1, -2, -8, -9), whereas short prodomain caspases (effector or executor) are 
activated by the former and operate as downstream amplifiers that cleave death 
substrates (e.g. caspase-3, -6, and -7) (Kumar, 1999; Earnshaw et al., 1999). 













1 ICE 45 CARD- CARDIAK (?) QACRG YEVD 
Long Prodomain / 
Cytokine processors
2 Nedd1, ICH1 51 CARD 
RAIDD/ 







32 - - QACRG DEVD Short Prodomain/ Apoptotic effector 
4 TX, Ich2, ICErII 43 CARD- - QACRG LEVD 
Long Prodomain/ 
Cytokine processors
5 TY, ICErIII 48 - - QACRG LEHD 
Long Prodomain / 
Cytokine processors





35 - - QACRG DEVD Short Prodomain/ Apoptosis effector 
8 FLICE, MACH 55 DED FADD QACQG IETD 
Long Prodomain/ 
Apoptotic initiator 
9 MCH6, ICELAP6 45 CARD APAF1 QACQG LEHD 
Long Prodomain/ 
Apoptotic initiator 
10 FLICE2, MCH4 55 DED FADD QACQG LEAD 
Long Prodomain/ 
Apoptotic initiator 
11  42 - -  WEHD Long Prodomain / Cytokine processors
12  50 - -  WEHD Long Prodomain / Cytokine processors
13 ERICE 43 - -  WEHD Long Prodomain / Cytokine processors
14 MICE 30 - -  WEHD Short Prodomain / Cytokine processors
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1.3.2. Caspase activation 
In general, initiator caspases act at the upstream of a proteolytic cascade in response to 
apoptotic stimulation, whereas downstream effector caspases at the are involved in the 
cleavage of a set of proteins, resulting in apoptotic death of the cell (Thornberry and 
Lazebnik, 1998). 
All caspases are expressed as proenzymes (30 to 55 kDa) that contain three domains: 
an NH2-terminal prodomain, a large subunit (~20 kDa), and a small subunit (~10 
kDa). Each active form of caspases is derived from two pro-caspases, which produce a 
heterotetramer composed of the two large subunits and the two small subunits from 
proteolytic processing between these domains (Thornberry and Lazebnik, 1998). This 
kind of tetrameric enzyme contains two active sites at opposite ends of the molecule 
(cf. Fig. 2, p. 14). Interestingly, this activation process can be performed by caspases 
themselves. Studies have showed that caspase 1 through 10 all are capable of auto-
processing (Earnshaw et al., 1999). The aggregation or oligomerisation of initiator 
caspase zymogens is sufficient to promote auto-processing/activation and, 
subsequently, trigger an avalanche of activation of other downstream effector caspases 
(Thornberry and Lazebnik, 1998).  
1.3.3. Adaptor proteins for caspase activation 
It is not entirely clear how the caspases with a large prodomain are activated, but their 
binding to adaptor molecules, which results in their oligomerisation and a series of 
autocatalysis and heteroproteolysis (Kumar, 1999; Earnshaw et al., 1999), is a critical 
step. Activation of initiator caspases by various apoptotic signals may be mediated by 
specific adaptors (Table 2 and Fig. 2). A good example is FADD/MORT1 (Fas-
associating death domain /mediator of receptor-induced toxicity 1). It possesses a 
motif known as the death effector domain (DED) which can interact with the DEDs in 
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the pro-domain of caspase-8. Subsequently, proteolytic processing by caspase-8 itself 
or other proteases releases active caspase-8 from the death-inducing signaling 
complex (DISC) (Medema et al., 1997). The other end of FADD has an interaction 
motif called death domain (DD) which binds to signalling molecules and receptors 
sending the death signal. Therefore, FADD acts as an adaptor by transducing the death 
signaling to caspase activation via its DD and DED. Another well described adaptor 
protein is RAIDD [receptor-interacting protein (RIP)-associated ICH-1/CED-3-
homologous protein with a death domain]. RAIDD also has a DD (Duan and Dixit, 
1997; Hofmann et al., 1997). Different to FADD, RAIDD does not possess a DED 
domain but a caspase recruitment domain (CARD) that binds to the CARD in the pro-
domain of caspase-2 (Duan and Dixit, 1997; Thome et al., 1998; Kumar, 1999; 
Earnshaw et al., 1999). This process is similar to the binding of DEDs between FADD 
and caspase-8. Thus these adaptors, including Apaf-1 [apoptotic protease activating 
factor-1, binding to cytochrome c] for caspase-9 and CARDIAK [CARD-containing 
interleukin (IL)-1 beta converting enzyme (ICE) associated kinase, interacting with 
the TNFR-associated factors] for caspase-1, possess both distinct domains responsible 
for their interactions with the upstream apoptotic molecules and with the prodomains 
of initiator caspases (Kumar, 1999; Earnshaw et al., 1999). Consequently, they may 
well be the targets regulated by other cellular signaling pathways. 
1.3.4. Apoptosis signaling 
Three apoptosis signalling pathways are summarized in Fig. 2. Two major caspase-
mediated apoptosis pathways have been well established (Kumar, 1999; Earnshaw et 
al., 1999). One involves the membrane death receptors [such as Fas antigen (CD95 or 
APO-1) and tumor-necrosis-factor receptor (TNFR)] which operate apoptotic death 
with caspase-8 acting as the upstream initiator in the cascade of caspase activation  




























Fig. 2. Apoptosis signalling pathways 
(Kumar, 1999; Earnshaw et al., 1999). Another cascade (initiated by caspase-9) of 
caspase activation is (independent of death receptor) involved in the apoptosis due to 
mitochondria damage (releasing cytochrome c) such as that caused by radiation and 
toxic drugs (Li et al., 1997b; Green and Reed, 1998; Ito et al., 1999). More recently it 
has been reported that caspase-12 mediates the apoptosis induced by ER stress by 
agents that release calcium from intracellular stores (Nakagawa et al., 2000), while 
caspase-11 is initially activated in the inflammatory LPS-induced cell death (Wang et 
al., 1998). 
1.3.5. Caspase substrates 
Many cellular substrates that undergo cleavage by caspases during apoptosis have 
been reviewed by Earnshaw et al (Earnshaw et al., 1999), including protein kinases, 
nuclear proteins, cytoskeletal proteins, proteins involved in signal transduction, cell 
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cycle regulation and DNA metabolism/repair, as well as caspases themselves. The 
plethora of caspase substrates indicates that caspases play an executive role in the 
destruction of the cell.  
However, growing evidence has showed that non-caspases, such as cathepsins, 
calpains, granzymes and the proteasome complex, may also mediate and promote cell 
death (Johnson, 2000).  
1.3.6. Caspase inhibitors 
The activity of caspases is regulated by their adaptors and other molecules such as the 
Bcl-2 family and FLIP (FLICE-inhibitory protein). In addition, some inhibitors 
directly interact with the proteases. For instance, viruses carry cell death inhibitors by 
binding to the activated caspases to block the response of host cells. The viral and 
cellular caspase inhibitors include cytokine response modifier A (CrmA), protease 
inhibitor 9 (PI-9, also known as granzyme B inhibitor), p35, and inhibitor of apoptosis 
proteins (IAPs) (reviewed by Ekert et al.). Importantly, many synthetic caspase 
inhibitors have been developed based on the substrate cleavage sites of the caspases 
for pharmacological and experimental use (Ekert et al., 1999). 
1.4. Cell cycle and apoptosis  
1.4.1. Cell cycle regulation: co-ordination of cyclins, CDKs and CKIs 
Cell cycle is co-ordinated by three families of molecules: cyclins, cyclin dependent 
kinases (CDKs), and cyclin dependent kinase inhibitors (CKIs) (Fig. 3) (Roberts et al., 
1994). CDKs, the central players which control the initiation, progression and 
completion of the cell cycle, are a group of protein kinases which must assemble into a 
holoenzyme with a cyclin subunit to become catalytically active. The function of the 
cyclin-CDK complex is regulated by phosphorylation of CDKs at different positions 
  
 Chapter 1 Introduction 
  16
G1 S G2 M
cyclin D1, D2 and D3 + 
Cdk2, 4, 5 and 6 cyclin A + Cdk2
cyclin A and 
B + Cdc2
cyclin E + Cdk2
p15, p16, p21 + p27 p21CKI
Cyclins & CDK
Cell cycle  
Fig. 3. Cell cycle regulators 
(activation) and by proteolysis of cyclins (inactivation) (Roberts et al., 1994). Active 
CDKs phosphorylate retinoplastoma protein (Rb) and histones, relieving cell cycle 
from blockade and promoting cell cycle progression. In mammalian cells, CDK-2, -3, 
-4 and –6 all function in G1 and /or S phase while the cdc2 (CDK1) appears to be 
restricted to mitosis (Sherr, 1993). The expression and role of each cyclin are also 
distinct in different phases of cell cycle. Cyclin B is critical for mitosis (Takizawa and 
Morgan, 2000), whereas cyclin A is essential during S phase and cyclin D and E are 
necessary in regulating the progression through G1 (Roberts et al., 1994; Takizawa 
and Morgan, 2000). During cell cycle, cells express D-type cyclins (D1-D3) in mid 
G1, cyclin E in late G1, cyclin A in S phase, and B-type cyclins in late G2 and mitosis. 
To antagonize the action of CDK-cyclin complexes in cell cycle, mammalian cells 
express two families of CKIs to bind and inhibit cyclin-CDK complexes: the p16 
family (INK4) and the p21WAF1/CIP1 family (Roberts et al., 1994; Sherr and Roberts, 
1999). The former family, including p15INK4b (Hannon and Beach, 1994), p16INK4a 
(Serrano et al., 1993), p18INK4c(Guan et al., 1994; Hirai et al., 1995) and p19INK4d(Hirai 
et al., 1995; Guan et al., 1996), specifically inhibits cyclin-D-CDK complexes, 
whereas the latter family (including p21WAF1/CIP1, p27KIP1 and p57KIP2) is capable of 
inactivating all known cyclin-CDK complexes. Expression of these two families of 
CKIs is induced by inhibitory regulators of cell cycle and occurs during normal state 
of growth arrest (Sherr and Roberts, 1999). 
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1.4.2. Cell cycle and apoptosis 
Apoptosis may occur at any stages of the cell cycle. Apoptosis is regarded as a process 
intimately linked to the cell cycle, since it is most frequently found in proliferating 
tissues and artificial manipulation of the cell cycle can either prevent or potentiate 
apoptosis (Meikrantz and Schlegel, 1995). Therefore, the transition from G1 to S 
phase is regarded as a crucial point for deciding the cell growth and apoptosis, because 
either normal division or mitotic catastrophe will be carried out depending on DNA 
synthesis in this state (Meikrantz and Schlegel, 1995). Particularly, cell progression 
from late G1 into S phase is regulated by p53 and by activation of CDKs in 
mammalian cells (El Deiry et al., 1993; Roberts et al., 1994; Meikrantz and Schlegel, 
1995). 
The growth suppressor p53 is a tightly regulated transcription factor that can induce 
either cell cycle arrest or apoptosis dictated by its expression levels in response to 
various stresses (Chen et al., 1996; Benchimol, 2001). In addition, p53 is particularly 
important for protecting cells when DNA is damaged by radiation, chemicals or viral 
infection (Cox and Lane, 1995). In this context, p53 is involved in the control of cell 
cycle in G1 and G2 phases (O'Connor, 1997; Mercer, 1998; Bunz et al., 1998; Taylor 
and Stark, 2001) by activating different target genes, such as p21WAF1/CIP1 (El Deiry et 
al., 1993), GADD45 (GADD, growth arrest and DNA damage-inducible) (Kastan et 
al., 1992) and 14-3-3σ (Taylor and Stark, 2001; Benchimol, 2001). 
1.4.3. p21WAF1/CIP1, p27KIP1 and cell cycle 
p21WAF1/CIP1 is a general inhibitor of cyclin-CDK complexes (Xiong et al., 1993). This 
protein is also given other names: WAF1 (wild-type p53-activated fragment 1) (El 
Deiry et al., 1993), CIP1 (Cdk-interacting protein 1) (Flores-Rozas et al., 1994; 
Harper et al., 1995), SDI1 (senescent cell-derived inhibitor 1) (Noda et al., 1994) or 
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MDA-6 (melanoma differentiation-associated protein). It has been reported that 
p21WAF1/CIP1 can act as either a downstream target/effector of p53 or independent of 
p53 (El Deiry et al., 1994; Alpan and Pardee, 1996) to coordinate the cellular 
responses to inhibitory growth signals  (El Deiry et al., 1993; Chiarugi et al., 1994; 
Gartel et al., 1996; Boulaire et al., 2000; Benchimol, 2001). An increase of this CKI 
molecule induces cell cycle arrest at G1 and blocks entry into S phase by inactivating 
CDKs or/and by inhibiting the activity of proliferating cell nuclear antigen (PCNA).  
p27KIP1 is another CKI and shares homology at the N-terminal CDK-inhibitory domain 
with p21WAF1/CIP1 (Polyak et al., 1994; Toyoshima and Hunter, 1994). It interacts with 
the cyclin/CDK complexes and suppresses the kinase activity of cyclin A-CDK2, 
cyclin D-CDK4, and cyclin E-CDK2 (Toyoshima and Hunter, 1994; Polyak et al., 
1994) by preventing their activation and inhibiting previously activated complexes 
(Toyoshima and Hunter, 1994; Polyak et al., 1994). p27KIP1 plays a role in the 
regulation of the progression through G1 and obstructs G1/S transition (Koff and 
Polyak, 1995; Zetterberg et al., 1995; Alessandrini et al., 1997; Moller, 2000). 
Different to p21WAF1/CIP1, induction of p27KIP1 expression is independent of p53 (An et 
al., 1998; Sowa et al., 1999; Zi and Agarwal, 1999; Patel et al., 2000; Pellizzaro et al., 
2001). 
1.5. GTP depletion and apoptosis 
1.5.1. GTP biosynthesis and IMP dehydrogenase (IMPDH) 
Normal intracellular levels of GTP (in the mM range) and other guanine nucleotides 
(GNs) modulate many biochemical reactions and their concentrations must be 
maintained at a critical level for normal cell signalling, metabolism, proliferation, 
differentiation, and other functions (Pall, 1985). GTP is necessary for the activation of  
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Fig. 3. Schematic representation of purine
nucleotides de novo and salvage pathways. Solid 
lines represent the plasma membrane. The 
following abbreviations are used: Ade, adenine; 
ext, extracellular medium; Gua, guanine; Hyp,
hypoxanthine; int, intracellular compartment; 
PRPP, 5-phosphoribosyl-1-pyrophosphate. Gene 
names are italicized and encode the following 
enzymatic activities: AAH1, adenine deaminase; 
APT1, adenine phosphoribosyltransferase; FCY2, 
purine cytosine permease; GUA1, guanosine-5'-
monophosphate synthetase; GUK1, guanosine-5'-
monophosphate kinase; HPT1, hypoxanthine-
guanine phosphoribosyltransferase; IMDs, inosine-
5'-monophosphate dehydrogenases; RNR, 
ribonucleotide reductase; YNK1, nucleoside-5'-
diphosphate kinase. (This figure is adapted from 
the paper of Mafalda Escobar-Henriques and 
Bertrand Daignan-Fornier. J. Biol. Chem. (2001), 
Vol. 276, Issue 2, 1523-1530)  
various GTP-binding proteins (G-proteins), for macromolecular synthesis (such as 
DNA, RNA and proteins), and is involved in signal transduction and exocytotic 
secretion (such as insulin release) (Jayaram et al., 1999; Metz and Kowluru, 1999; 
Metz et al., 2001). Moreover, GTP may be required for some other functions, such as 
ATP synthesis, calcium mobilization, microtubule assembly, vesicle traffic and protein 
kinase regulation (Metz et al., 1992).  
Inosine 5'-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) is a rate-limiting 
enzyme in the de novo synthesis of GTP and other GNs (Metz and Kowluru, 1999; 
Allison and Eugui, 2000; Metz et al., 2001) (Fig 4). IMPDH catalyzes the NAD-
dependent conversion of inosine 5'-monophosphate (IMP) to xanthine 5'-
monophosphate (XMP), which is further converted to guanosine monophosphate 
(GMP) by GMP synthase and, subsequently, to guanosine diphosphate (GDP) by 
GUK1, and finally to GTP by YNK1 (Metz and Kowluru, 1999; Jayaram et al., 1999; 
Allison and Eugui, 2000; Escobar-Henriques and Daignan-Fornier, 2001). The only 
alternative pathway for GTP biosynthesis is through the salvage of guanine to GMP by 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). The relative contributions 
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of the de novo and salvage pathways to GTP biosynthesis in different tissues and cell 
types have not been definitively determined. However, both the pathophysiology of 
inherited disorders of enzymes and the therapeutic effects of selected pharmacological 
inhibitors of these enzymes are well investigated to date (Gu et al., 2002). 
There are two IMPDH isoenzymes, termed type I and type II. They are 84% identical 
at the amino acid level and possess indistinguishable catalytic activity. However, the 
regulation of expression of the two IMPDH genes differs dramatically. The increased 
IMPDH activity observed in replicating or neoplastic cells is largely due to increased 
expression of the type II IMPDH mRNA, whereas expression of the type I gene is 
relatively unaffected by cell proliferation or transformation (Nagai et al., 1991; Nagai, 
2002). Type I IMPDH is constitutively expressed, whereas type II is upregulated in 
proliferating cells (due to higher rate of GTP production required for DNA synthesis), 
and highly down-regulated in terminally differentiated cells (due to relatively lower 
GTP synthesis for “housekeeping” and RNA synthesis) (Nagai et al., 1991; Carr et al., 
1993; Natsumeda and Carr, 1993; Yalowitz and Jayaram, 2000). IMPDH gene 
expression is regulated inversely by a posttranscriptional nuclear event in response to 
fluctuations in the intracellular level of GNs (Azim et al., 1996).  
Interestingly, IMPDH may be a rate-determining factor for p53-dependent cell growth 
regulation (Liu et al., 1998a). Sherley et al have demonstrated that p53 not only down-
regulates IMPDH expression (Sherley et al., 1995; Liu et al., 1998a), but also 
selectively reduces IMPDH enzymatic activity (Sherley, 1991; Stadler et al., 1994). 
Recently, Kelly et al showed that supplement of guanosine reverses p53 increment in 
apoptosis induced by ischemic injury in tubular cells, whereas a specific inhibitor of 
p53 (Pifithrin-alpha) mimics the effects of guanosine to prevent apoptosis and protect 
renal function. (Kelly et al., 2003). 
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1.5.2. IMPDH inhibitors 
Several structurally distinct IMPDH inhibitors have been identified. Some belong to 
the family of nucleoside compounds (including tiazofurin, selenazofurin, and 
benzamide riboside) which are anabolized to IMP analogues are able to inhibit 
IMPDH. Mizoribine (MZ) is also a competitive inhibitor of IMPDH. Contrary to MZ, 
mycophenolic acid (MPA) is a non-nucleoside IMPDH inhibitor showing 
uncompetitive inhibition with a Ki of 156 nM versus NAD (Carr et al., 1993; Halloran 
1996, Yalowitz and Jayaram, 2000). 
Since IMPDH has higher activity in proliferating than in quiescent cells, specific 
inhibitors of IMPDH have been widely used to treat cancers and psoriasis and more 
recently to prevent transplantation rejection (Jackson RC, 1975; Natsumeda et al., 
1988; Luchetti et al., 1999). Many inhibitors of IMPDH are used clinically as antiviral 
(e.g. ribavirin), antitumor (e.g. tiazofurin, selenazofurin, and benzamide riboside), and 
immunosuppressive (e.g. MPA) drugs (Yalowitz and Jayaram, 2000).  
These specific inhibitors interfere with cell proliferation and differentiation (Grusch et 
al., 1999; Jayaram et al., 1999). GTP depletion (down to µM ranges) by inhibition of 
IMPDH alone is capable of blocking RNA-primed DNA synthesis in the presence of 
all other rNTPs and dNTPs, including dGTP (Cohen et al., 1981). Generally speaking, 
growth inhibition by GTP depletion is a conserved pathway from Bacillus to humans 
(Yalowitz and Jayaram, 2000). In addition, GTP depletion may induce apoptosis as 
demonstrated in several types of cells (Catapano et al., 1995; Li et al., 1998; Metz and 
Kowluru, 1999; Hauser et al., 1999; Jayaram et al., 1999; Cohn et al., 1999; Yalowitz 
and Jayaram, 2000). Thus GTP depletion is a potent signal for arrest of cell 
proliferation and induction of apoptosis. 
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1.5.3. Mycophenolic acid (MPA) 
Gosio firstly isolated MPA from a Penicillium culture in 1896. Alsberg and Black 
confirmed this work and gave the substance its current name in 1913. Raistrick et al 
illustrated the MPA structure in 1952 (Fig 5). MPA was found to have limited 
antibacterial and antifungal activity by some researchers including Abraham (in 1945), 
Florey, Gilliver and Jennings (in 1946). Importantly, Carter found that MPA has a 
potent antimitotic effect in mammalian cells and demonstrated that it is an effective 
antitumor agent (Williams et al., 1968; Carter et al., 1969). Recently, MPA is also 
widely used as a selective potent immunosuppressant to control cellular and antibody- 
mediated rejection in host tissues (Lanford et al., 2001). This is because antigen-
activated B and T cells are highly dependent on purine de novo synthesis, whereas 
most other cells are capable of utilizing a salvage pathway. 
MPA is a specific IMPDH inhibitor (Allison and Eugui, 2000). MPA depletes cellular 
GNs, leading to partial reduction in RNA synthesis and drastic inhibition of DNA 
synthesis; these inhibitory effects can be entirely reversed by provision of guanine or 
guanosine (but not by hypoxanthine, xanthine, adenine or adenosine) in a non-
competitive manner (Franklin and Cook, 1969; Lowe et al., 1977; Nguyen and Sadee, 








Fig 5. Structure of mycophenolic acid  
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may result in growth arrest and induction of apoptosis (Franklin and Cook, 1969; Metz 
and Kowluru, 1999; Yalowitz and Jayaram, 2000; Allison and Eugui, 2000; Allison, 
2000).  
Type II IMPDH is more sensitive to inhibition by MPA than the type I isoform 
(Luchetti et al., 1999). Of existing IMPDH inhibitors, MPA is the only one that has 
been shown to have preferable inhibition to the type II isoform of IMPDH (Yalowitz 
and Jayaram, 2000), with a 4.8- fold lower Ki than the type I (Allison and Eugui, 
2000). 
1.5.4. IMPDH in β-cells 
Metz et al found that IMPDH expression is modulated by GN levels in insulin 
secreting cells (Metz et al., 2001). IMPDH is involved in both secretory and 
proliferation processes in β-cells (Li et al., 1998; Metz and Kowluru, 1999; Metz et al., 
2001). It has been demonstrated that short-term depletion of GTP by using IMPDH 
inhibitors altered membrane ion fluxes and inhibited insulin secretion in islet β-cells 
(Metz et al., 1992; Meredith et al., 1997; Detimary et al., 1997; Komatsu et al., 1998; 
Metz and Kowluru, 1999; Li et al., 2000). The latter effect was probably due in part to 
the interference with the activation of phospholipase C and certain G-proteins 
(Kowluru et al., 1996). On the other hand, long-term inhibition of IMPDH arrested β-
cell growth and triggered apoptosis (see below). Thus sufficient IMPDH activity (and 
thereby, availability of GTP) is important for the maintenance of insulin secretion and 
replication capability in β cells.  
1.5.5. MPA and apoptosis of insulin secreting cells  
A balance between β-cell proliferation and programmed cell death is important for the 
maintenance of β-cell mass necessary for secreting insulin to meet the body’s 
requirement. There is evidence for a role of IMPDH in maintaining this balance. For 
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instance, interleukin-1β caused a reduction of GNs (Meredith et al., 1996) and 
apoptosis (Iwahashi et al., 1996) in islet β-cells. 
Induction of apoptosis of β-cells (HIT-T15 cells, INS-1 cells and intact adult rat islets) 
by prolonged depletion of cellular GTP by two structurally-distinct IMPDH inhibitors 
(MPA and mizoribine) was first reported by Li et al (Li et al., 1998). HIT-T15 is a β-
cell line derived from Syrian hamster islets transformed by SV40, whereas INS-1 cells 
were derived from radiation-induced rat β-cell tumors (Asfari et al, 1992). Noticeably, 
HIT-T15 cells are more sensitive to the inhibitory effects of MPA on GN synthesis 
than INS-1 cells or islets cells, due to a weak salvage pathway in the former cells 
(Meredith et al., 1997).  
In the study by Li et al, sustained depletion of GTP caused inhibition of mitogenesis, 
decrement of cell number, DNA, protein content, and decline of metabolic viability in 
β-cells. These cells revealed typical apoptotic characters, such as apoptotic bodies, 
marginated chromatin, cytosolic vacuolization, loss of microvilli, and DNA 
fragmentation as assessed morphologically by electron microscopic observations (Fig. 
6) and biochemically by DNA fragmentation (laddering). In addition, this kind of cell 
death was almost totally prevented by supplementation with guanosine, but not with 
adenosine, indicating that this is a specific effect of GTP depletion. However, the 
apoptosis induced by GTP depletion is not mediated by dGTP reduction because both 
low (30 µM) and high (500 µM) concentrations of exogenous deoxyguanosine, which 
could restore the dGTP content of cells even at 25 µM, failed to prevent the effect of 
MPA on cell death. How GN-depletion inhibits mitogenesis and induces apoptosis was 
unclear, although it might be due to the combined effects of inhibition of primer RNA 
biosynthesis and the interference with the function of some small G-proteins.  
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Fig. 6. Prolonged MPA treatment 
induced apoptotic changes in HIT-
T15 cells. After treatment with 3 
µg/ml MPA for 48 hrs, HIT cells 
cultured on glass coverslips were 
fixed and examined by electron 
microscopy. a, Control; b and c, 
treated with 3 µg/ml MPA for 2 days. 
In c, one cell (open arrow) was at the 
early stage of apoptosis, and two cells 
(solid arrow) were at the later stage of 
apoptosis. Bars in a and b = 1 µm; 
bar in c = 2 µm. This figure is 
adapted from the paper of Li et al. 
(1998) (Endocrinology, Vol. 139, No. 
9, 3752-3762)
 
1.6. Aim of this study 
IMPDH is a rate-limiting enzyme for the synthesis of GTP, dGTP and GNs (Jayaram 
et al., 1999; Metz and Kowluru, 1999). Alterations in the expression or activity of 
IMPDH affect cell proliferation, differentiation and apoptosis (Catapano et al., 1995; 
Li et al., 1998; Jayaram et al., 1999; Cohn et al., 1999; Metz et al., 2001). These 
effects may be mediated directly by GTP or indirectly via GTP-binding proteins (Metz 
and Kowluru, 1999). Based on the previous work (Li et al., 1998), this study has 
focused on the following three topics to define the mechanism underlying the 
apoptosis of insulin-secreting cells induced by GTP depletion with MPA treatment. 
1.6.1. Does tTG participate in MPA induced β-cell apoptosis? 
As described above, tTG is a unique protein with dual functions, cross-linking of 
polypeptides and coupling of certain receptors to phospholipase C (Feng et al., 1996; 
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Feng et al., 1999). In recent years the results from some studies suggest tTG may be 
also involved in the initiation of apoptosis. Increases of tTG expression and/or activity 
of tTG were observed during apoptotic cell death under various circumstances 
(Autuori et al., 1998). It is known that tTG activity is regulated by the levels of both 
Ca2+ and GTP in the cells; an increase of the former or a reduction in the latter 
stimulates tTG activity (Melino et al., 1998). Moreover, earlier work found that MPA 
specifically caused dramatic decreases of GTP level (by 71-74%) and GTP/GDP ratio 
(by 43-46%) after 18-h treatment in HIT cells (Meredith, 1997). Therefore, it is likely 
that tTG activity in β-cells would be elevated by GTP depletion due to MPA.  
In the light of the above observations, this work aimed at evaluating the possible 
involvment of tTG in MPA-induced apoptotic death in HIT cells. We tried to examine 
the change of tTG activity after treatment of cells with different concentrations of 
MPA for various time periods, in order to find the possible relationship between tTG 
activity and MPA-induced apoptosis. In addition, the possible role of tTG in apoptosis 
due to GTP depletion was also examined by using tTG inhibitors (such as 
monodansylcadaverine and putrescine, or by lowering free Ca 2+
 
concentrations in 
culture medium) to potentially block the cell death.  
1.6.2. Is any caspase involved in MPA induced β-cell apoptosis?  
Apoptosis may or may not involve caspases. In most cases, however, activation of 
caspases plays a critical role as either initiators or effectors in the execution of 
apoptotic cell death (Kumar, 1999; Earnshaw et al., 1999). Since it was unclear 
whether any caspase is implicated in GTP-depletion induced apoptosis of insulin-
secreting cells, a goal of this study was to address this issue by measuring the activity 
of caspase-1 through caspase-10 after MPA treatment for various periods to identify 
the potential initiative and executive caspases. Furthermore, the role of caspases in 
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GTP-depletion induced cell death was also investigated by using selective caspase 
inhibitors. 
1.6.3. Is any cell cycle regulator(s) important for MPA-induced β-cell apoptosis? 
Apoptosis may occur at any stages of the cell cycle. However, the transition from G1 
to S phase is regarded as a crucial point for deciding the cell growth and apoptosis 
and, in particular, cell progression from late G1 into S phase is regulated in many cells 
by p53 and CDKs (El Deiry et al., 1993; Roberts et al., 1994; Meikrantz and Schlegel, 
1995). Several studies have also suggested the importance of cell cycle molecules in 
islet β-cell growth and death and in the induction of diabetes (Zhang et al., 1999b; 
Kaneto et al., 1999a; Rane et al., 1999; Tsutsui et al., 1999).  
MPA depletes cellular GNs, which causes partial reduction in RNA synthesis and 
drastic inhibition of DNA synthesis, resulting in growth arrest and induction of 
apoptosis (Li et al., 1998; Cohn et al., 1999; Metz and Kowluru, 1999; Allison and 
Eugui, 2000; Yalowitz and Jayaram, 2000). However, little is known about the 
relationship between inhibition of mitogenesis and induction of apoptotic death due to 
GN depletion in insulin-secreting cells. It has been reported that MPA inhibited cell 
proliferation by specifically affecting the cells in S phase (Cohen et al., 1981; Nguyen 
et al., 1984; Knight et al., 1993; Cohn et al., 1999), while other studies indicated that 
an inhibition of de novo GNs synthesis blocked the transition of cell cycle from G1 to 
S phase (Laliberte et al., 1998). Interestingly, p53 may interact with IMPDH since the 
former down-regulated IMPDH activity and its protein and mRNA levels (Sherley, 
1991; Liu et al., 1998b; Liu et al., 1998a; Yalowitz and Jayaram, 2000). Accordingly, 
it is possible (and previously unexplored) that the expression of some cell-cycle 
regulating proteins may be changed and implicated in β-cell apoptosis triggered by 
GTP depletion. In this study, we examined the levels of three important cell-cycle 
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regulators (p53, p27KIP1 and p21WAF1/CIP1) in the course of induction of apoptosis of 
HIT-T15 cells by GTP depletion, in order to investigate their role in this scenario. 
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Chapter 2 
Materials and Methods 
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2.1. Materials 
General laboratory chemicals and solvents were of reagent grade. Special reagents and 
chemicals used in this study are listed below in detail according to their sources: 
BIOMOL, Plymouth Meeting, PA, USA 
N-acetyl-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Tyr-
Val-Ala-Asp-aldehyde, YVAD-CHO, a specific inhibitor for caspase-1 
Boehringer Mannheim GmbH, Mannheim, Germany 
Ac-leu-leu-argininal·½ H2SO4 (leupeptin) 
N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] (HEPES) 
Sheep polyclonal anti-p53 (wild and mutant) antibody conjugated with peroxidase, 
anti-p53-protein-POD (polyclonal BMG-1B1) 
Bio-Rad Laboratories, Hercules, CA, USA 
Acetyl- Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin (Ac-DEVD-AFC), a 
specific substrate for caspase-3, -7 and -10 
Acetyl- Leu-Glu-His-Asp-7-amino-4-trifluoromethyl coumarin (Ac-LEHD-AFC), a 
specific substrate for caspase-9 
Acetyl- Leu-Glu-Thr-Asp-7-amino-4-trifluoromethyl coumarin (Ac-LETD-AFC), a 
specific substrate for caspase-8 
Acetyl-Trp-Glu-His-Asp-7-amino-4-trifluoromethyl coumarin (Ac-WEHD-AFC), a 
specific substrate for caspase-1, -4 and -5 
Acetyl-Val-Asp-Val-Ala-Asp-7-amino-4-trifluoromethyl coumarin (Ac-VDVAD-
AFC), a specific substrate for caspase-2 
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Acetyl-Val-Glu-Ile-Asp-7-amino-4-trifluoromethyl coumarin (Ac-VEID-AFC), a 
specific substrate for caspase-6 
N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK), a general 
inhibitor for caspases 
N-benzyloxycarbonyl-Val-Asp-Val-Ala-Asp-fluoromethylketone (Z-VDVAD-FMK), 
a specific inhibitor for caspase-2 
Bio-Rad Protein Assay Dye Reagent Concentrate and protein standard 
Coomassie Brilliant Blue R-250 (protein assay dye reagent) 
Immun-blot polyvinylidine difluoride (PVDF) (0.45 µm) membrane 
Kaleidoscope prestained standards 
Nitrocellulose membrane (0.45 µm) 
Stock solution for eletrophoresis, 30% Acrylamide/N, N’-methylenbisacrylamide 
(total monomer to crosslinker ratio at 37.5:1) 
Biosource International, Nivelles, Belgium 
Interleukin-1β, human recombinant protein 
Calbiochem, La Jolla, CA 
Caspase-3 inhibitor (DEVD-CHO, N-acetyl-Asp-Glu-Val-Asp-aldehyde) 
E. Merck, Germany 
β-Mercaptoethanol 
Dimethyl sulphoxide (DMSO) 
Formamide 
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Paraformaldehyde  
Fisher Scientific, Leicestershire, UK 
N-butanol 
Tween-20 
Gibco-Invitrogen Corporation, NK, USA 
Bovine serum albumin (BSA) 
Fetal calf serum (FCS) 
New born calf serum (NBCS) 
Protein A agarose 
J. T. Baker, Phillipsburg, NJ, USA 
Tris hydroxymethyl-aminomethane (Tris) 
NeoMakers,Fremont, CA, USA 
Tubulin-β Ab-4, positive loading control for Western blotting 
ICN Biomedicals Inc, Aurora, OH, USA 
3-(3-cholamidopropyl) dimethylammonio-1-propane sulfonate (CHAPS) 
PhamMingen, San Diego, CA; 
Polyclonal rabbit anti-caspase-3 (CPP-32, YAMA, APOPAIN) antibody 
Purified mouse anti-cytochrome c monoclonal antibody (7H8.2C12, mouse IgG2b) 
Purified mouse anti-human caspase-2 (ICH-1) monoclonal antibody 
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Pharmacia Biotech AB, Sweden 
Ammonium persulphate (ASP) 
Bromophenol blue  
Tetramethylethylenediamine (TEMED) 
Pierce, Rockford, IL, USA 
5-(biotinamido) pentylamine, horseradish peroxidase (HRP)-conjugated streptavidin 
Anti-Goat IgG, (H+L), peroxidase conjugated 
Anti-rabbit IgG peroxidase conjugate 
EZ-link 5-(biotinamido) pentylamine 
Streptavidin, horseradish peroxidase conjugated 
Supersignal West Dura; extended duration substrate 
Supersignal West Pico; chemiluminescent substrate 
Western blotting stripping buffer 
Promega Corporation, Madison, WI, USA 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) 
Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Affinity-purified polyclonal antibody (from goat) of p21WAF1/CIP1 (c-19) 
Affinity-purified polyclonal antibody (from goat) of p27KIP1 (c-19) 
Anti-goat Ig G-HRP conjugated 
Anti-mouse IgG-HRP conjugated 
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Anti-rabbit IgG-HRP conjugate 
Anti-RAIDD, rabbit polyclonal IgG 
RAIDD (full length), Western blotting positive control 
Sigma Chemical Co., St. Louis, MO, USA 
Adenosine 
Aprotinin 
Bisbenzimidazole dye Hoechst 33258 (H33258) 
Diethylpyrocarbonate (DEPC) 
Dithiothreitol (DTT) 
DNA standard (sodium salt, from calf thymus) 
Ethidium bromide (EB) 
Ethylene Glycol-bis (β-Aminoethyl ether)-N, N, N’N’-Tetraacetic acid (EGTA) 
Ethylenediaminetetraacetic acid (EDTA) 
Guanosine 
Interleukin-1-β, rat recombinant 
LDH assay kits (Cat. No. 228-100P) 
Leupeptin, trifluroacetate salt 
L-mimosine 
Monodansylcadaverine (MDC) 
Mouse monoclonal anti-β-tubulin 
Mycophenolic acid (MPA) 
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N- [2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) 
o-phenylenediamine dihydrochloride  
Penicillin  
Pepstatin A 




RPMI 1640 medium, with L-glutamine and without sodium bicarbonate 
Sodium dodecyl sulphate (SDS) 
Streptomycin 
Triton X-100 
Upstate Biotechnology, Lake Placid, NY, USA 
Anti-type II transglutaminase (goat polyclonal IgG)  
2.2. Methods 
2.2.1. Cell culture and storage 
Cell culture 
In this study, insulin-secreting HIT-T15 cells (passage 76-83) were used. The cells 
were maintained in RPMI 1640 supplemented with 10% decomplemented fetal calf 
serum (v/v), 100 i.u. penicillin/ml and 100 µg streptomycin/ml in a 5% CO2 incubator 
at 37oC. The cells were harvested upon reaching confluence, and passed weekly by 
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trypsinization and seeding at a density of 1.0 x 106 /ml in culture dishes. The culture 
medium was changed every 48 hrs.  
During passing, the cells were rinsed with 37oC phosphate-buffered saline (PBS) and 
incubated in 0.025% trypsin [5:45:50 of 0.5% trypsin stock: PBS (Ca/Mg-free): EDTA 
(0.54 mM)] for 5-8 min to detachment. Cold RPMI 1640 with 10% new born calf 
serum (NBCS) was added to terminate trypsinization. The resulting cell suspension 
was centrifuged at 130 x g at room temperature for 5 min. After discarding the 
supernatant, the cells were resuspended in RPMI 1640 with 10% fetal calf serum plus 
antibiotics and ready for seeding. 
For experiments, cells were seeded in dishes or multi-well plates. When cells had 
approached more than 80% confluence, test agents were added to the medium for 
treatment of various time periods. 
Cell storage 
After washing the trypsinised cells with culture medium, they were resuspended in 1 
ml of freezing medium (RPMI 1640 containing 20% fetal calf serum, 10% DMSO) 
and pipetted into cryo-tubes (around 1x106 cells). The tubes were packed with a cotton 
pad in a polystyrene box and placed at 4oC for half an hour. The box was then left at –
70oC overnight, and the cryo-tubes finally transferred into a liquid nitrogen tank for 
long term storage. 
2.2.2. Detection of apoptosis by MTS test and DNA content determination 
Sustained (24-48 hrs) treatment of HIT cells with MPA caused apoptosis (Li et al., 
1998). MPA stock solution (2 mg/ml) was prepared in ethanol and added into culture 
medium directly to reach final concentrations of 0.01-10 µg/ml for up to 48 hrs.  
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MPA-induced apoptosis of HIT cells was evaluated by MTS test and DNA content (Li 
et al., 1998). Our previous studies have demonstrated that these assessments are good 
markers to monitor GN-depletion induced apoptotic cell death which had been 
formally established by more specific means such as electron microscopic examination 
and measurements of DNA-laddering (Li et al., 1998). 
Cell metabolic viability was monitored by MTS test, which detects reduction of a 
tetrazolium salt into a colored and water-soluble formazan in intact cells (Cory et al., 
1991; Segu et al., 1998; Li et al., 1998; Huo et al., 2002). Dehydrogenases in 
metabolically functional cells accomplish the conversion of MTS into the formazan 
using PMS as the electron-coupling reagent (Cory et al., 1991). HIT cells cultured on 
96-well plates were treated with test agents for various periods of time. After one 
gentle wash to discard culture medium and any floating cells, a mixture of MTS and 
PMS in fresh RPMI 1640 was added in the wells and the plates were incubated for 30 
min. The absorbance of the formazan at 490 nm was measured in 96-well plates using 
a plate reader. We have confirmed that the intensity of absorbance from formazan 
product is proportional to the number of control living cells added into the wells. 
For assessing cell death by determination of DNA content, cells seeded in microtiter 
plates were washed to remove culture medium and any floating cells. The attached 
cells were lyzed by sonication in distilled water. Aliquots of the cell lysates were 
reacted with the fluorescent DNA-binding dye, Hoechst 33258 (Rago et al., 1990), in 
96-well plates. The fluorescence was measured by a fluorescent plate reader 
(SPECTRAmaxTM GEMINI, from Molecular Devices, Sunnyvale, CA) at excitation 
and emission wavelengths of 356 nm and 448 nm, respectively. DNA contents in the 
wells were calculated by comparison with the standard curves. 
 Chapter 2 Materials and Methods 
  38
The raw values from MTS test and DNA measurements were affected by many factors 
such as cell numbers, probe concentrations and equipment function. Indeed, there is 
variance in the cell numbers used between experiments, as well as between time points 
for controls due to proliferation and for treated cells due to cell loss. As a 
consequence, it is difficult to compare the raw data between individual experiments 
(including the different time points of treatment within one experiment) and to pool 
the data for statistical analyses. Therefore, we always measured the samples of both 
treated cells and control cells at any time point (they were seeded at the same time in 
triplicate each) and calculated the mean values for each condition. Afterwards, the 
ratio of mean values of treated samples was expressed as percentage of control. In this 
way, the change due to a given treatment (dose or time) could be assessed more 
precisely. 
2.2.3. Flow cytometric analysis for DNA fragmentation and cell cycle 
Cell cycle were determined by propidium iodide (PI) staining and flow cytometry as 
described by Nicoletti et al (Nicoletti et al., 1991). This assay is also able to measure 
the fragmented nuclei and thus detect the subdiploidy apoptosis (Nicoletti et al., 1991). 
PI is the most widely used dye for the analysis of DNA by flow cytometry. It stains all 
double-stranded regions of both DNA and RNA by intercalating between the stacked 
bases of the double helix. The dye can not penetrate an intact cell membrane and, 
therefore, permeabilization such as ethanol fixation is necessary. 
In this study, HIT cells were cultured in 6-well plates with 3 µg/ml MPA for 8-48 hrs. 
After one gentle rinse by PBS, the cells were collected by trypsinization and 
centrifugation. Then the cell pellets were gently resuspended thoroughly in 0.5 ml PBS 
followed by 2-h fixation (at 4oC) in 4.5 ml 70% ethanol. Cells suspended in 70% 
ethanol were stored at -20oC if PI staining was not performed immediately. For PI 
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staining, the ethanol suspended cells were centrifuged for 5 min at 200 x g to remove 
cell debris. The cell pellets were re-suspended in 5 ml PBS and centrifuged for 5 min 
at 200 x g. Afterward, the cells pellets were incubated in 1 ml PI/Triton X-100 staining 
solution (containing 20 µg/ml PI, 0.1% Triton X-100 and 0.2 mg/ml RNAse A in PBS) 
for 30 min at room temperature. Flow cytometric analysis was carried out using a 
fluorescence-activated-cell-sorter (EPICS Elite ESP, Beckman Coulter, Hialeah, FL). 
An excitation source of 488 nm was achieved using a 15 mW air-cooled argon-ion 
laser. Fluorescence emission was collected through a 610 nm band pass filter for PI. PI 
fluorescence data were collected on a linear scale. Ten-thousand cells were evaluated 
for each sample. The flow rate was kept at 200-300 cells/sec. The data were processed 
and analyzed using WinMDI software (Scripps Institute, La Jolla, CA).  
The number of floating and rinsed cells not included in the flow cytometric analysis 
and other two apoptotic assays (MTS test and DNA measurements) was varied 
depending on the time periods of MPA treatments (5.7%, 7.3%, 8.3%, 9.3%, 12.8%, 
19% and 33.9% at 0, 8, 16, 24, 32, 40 and 48 hrs, respectively; n=3). Almost all of 
these cells (>94%) were dead cells or apoptotic cells as assessed by PI staining and 
flow cytometry. 
2.2.4. Protein concentration assay 
Protein contents were measured by Bio-Rad assay based on the change of absorption 
of Coomassie brilliant blue G-250 dye (shifts from 465 nm to 595 nm when binding to 
protein) in response to various concentrations of protein. The dye binds primarily to 
basic (especially arginine) and aromatic amino acid residues. The assay is useful for 
measuring proteins and polypeptides with MW greater than 3,000-5,000, depending on 
the charged groups. 
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Aliquots of samples or protein standard (181.25-1,450 µg/ml) were mixed with the 
reagent in 96-well plates and incubated at room temperature for 10 min. The 
absorbance at 595 nm was measured with a microplate reader. The protein 
concentrations in samples were calculated by comparing the standard curve obtained 
from known concentrations of protein which was run in parallel. 
2.2.5. Assay of in situ tTG activity 
In situ tTG activity was measured in cell extracts following the procedures by Zhang 
et al, in which a biotinylated tTG substrate was loaded into living cells and the 
generated product was measured by a streptavidin-linked enzyme assay (Zhang et al., 
1998).  
HIT-T15 cells were cultured in 24-well plates and treated with different concentrations 
of MPA alone or combined with other test agents for 24 or 48 hrs. On the day of the 
experiment, cells were pre-incubated in 250 µl Krebs-Ringer-bicarbonate-Hepes 
(KRBH) buffer (supplemented with 0.1% BSA and 10 mM glucose) containing 2 mM 
of the tTG substrate, 5-(biotinamido) pentylamine, for 1 hr. After one wash with cold 
PBS, 0.2 ml homogenizing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 µg/ml each of 
aprotinin, leupeptin, and pepstatin) was added to each well and cells were subjected to 
sonication (3 x 10 sec) on ice. Protein contents were determined by Bio-Rad assay. 
Subsequently, 10 µg of homogenate protein was diluted to 50 µl with coating buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA) and added to 
the 96-well microtiter plates. After incubation overnight at 4oC, 200 µl of blocking 
buffer [100 mM boric acid, 20 mM sodium borate, 80 mM NaCl (BBS) containing 5% 
BSA, 0.01% Tween-20, and 0.01 % SDS] was added to each well. The plates were 
incubated for 2 hrs at 37oC. After one wash with a rinse buffer (BBS supplemented 
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with 1% BSA and 0.01% Tween-20), 100 µl of horseradish peroxidase (HRP)-
conjugated streptavidin (1:2000) in BBS with 1% BSA and 0.01% Tween-20 was 
added and the plates were left at room temperature for 1 hr. After 4 rinses, 200 µl of 
substrate solution (0.04% O-phenylenediamine dihydrochloride in 50 mM sodium 
citrate phosphate buffer, pH 5.0) was added to each well. The plates were incubated at 
room temperature for 15 min and the reaction was terminated by adding 50 µl of 3 M 
HCl. Optical density of HRP-generated product was measured with a plate reader at 
492 nm. tTG activity was expressed as the percentage of basal activity in control 
samples. 
2.2.6. Caspase activity measurement 
Measurements of caspase activity are simplified by using fluorogenic synthetic 
oligopeptide substrates (Komoriya et al., 2000). These amino acid sequences are 
identical or similar to those found in full-length protein substrates, and where 
differences occur, the optimized synthetic substrates appear to be cleaved as efficiently 
or better than the full-length proteins. Substrates are synthesized by modifying the 
caspase cleavage site (C-terminal aspartic acid) with 7-amino-4-trifluoromethyl 
coumarin (AFC). When liberated from the peptide, AFC produces an optical change 
resulting in emissions of fluorescence.  
HIT cells were cultured in 6-well plates. For each independent experiment, duplicates 
of both control and treated wells were applied for any time point of treatment. Activity 
of individual caspase in samples from control and treated cells at any time point of 
treatment was measured and compared. The results were expressed as percentage of 
control. After decanting medium and rinsing cells with cold PBS, 100 µl lysis buffer 
(10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 350 µg/ml PMSF, 
10 µg/ml pepstatin A, 10 µg/ml aprotinin and 20 µg/ml leupeptin) was added to each 
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well and cells were scraped with a cell lifter and transferred to clean tubes. The tubes 
were frozen and thawed for 4 cycles to lyze the cells by transferring from a -20oC 
freezer to a 37oC water bath. Lysates were centrifuged (Eppendorf) at 4oC for 30 min 
at full speed. The supernatants were transferred to clean tubes and kept on ice if the 
assay was to be performed within 1 hr or, otherwise, stored at -70oC. The caspase 
activity assay was performed according to the protocol provided by the supplier. In 
brief, the reaction components containing caspase substrates were thoroughly mixed 
with a blank or test samples in a 96-well microtiter plate. After incubation at 37oC for 
3 hrs, the plates were scanned by a fluorescent plate reader to measure the AFC 
fluorescence at excitation and emission wavelengths of 395 nm and 525 nm, 
respectively. The increase in AFC fluorescence signal was proportional to the enzyme 
activity. All values were corrected by blank readings and the enzyme activity was 
normalized to a fixed protein concentration.  
2.2.7. Isolation of mitochondria-enriched and cytosolic fractions 
All following steps were performed at 4oC as described previously (Li et al., 1996). 
After washing with cold PBS, HIT cells were detached by scraping and suspended in 
homogenization buffer containing20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM 
EGTA, 250 mM sucrose, 1 mM DTT and the following protease inhibitors (in µg/ml): 
10 leupeptin, 4 aprotinin, 2 pepstatin and 100 PMSF. The cells were first subjected to 
cavitation in a nitrogen bomb (from Parr) under 10 bars for 30 min and then the 
achieved cell suspensions were further homogenized by using a Dunce tissue grinder 
(from Kontes) with the tight pestle. The homogenates were centrifuged at 900 x g for 
10 min to remove unbroken cells and nuclei. The supernatants were then centrifuged at 
5,500 x g for 20 min. The pellets (rich in mitochondria) were resuspended in 
homogenization buffer and sonicated for 3 times (5 sec each). Cytosol was achieved 
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by centrifuging the post-mitochondrial supernatant at 100,000 x g for 60 min. Protein 
concentrations were determined and samples were aliquoted and kept at -70oC. 
2.2.8. Examination of cell morphology 
HIT cells were cultured on chambered coverglass (Nalge Nuce, Naperville, IL) with 
test agents for indicated time periods. Non-adherent cells were removed by changing 
medium. Morphology of living cells was examined under differential interference 
contrast (DIC) by a Curl Zeiss confocal microscope (objective: Plan-Neofluar, 
20x/0.5). 
2.2.9. Immunoprecipitation of RAIDD and caspase-2 
HIT cells cultured in 6-well plates were treated with MPA (3 µg/ml) for indicated time 
periods. All procedures below were performed at 4oC. After washing in cold PBS 
buffer, the cells were lysed in cold immunoprecipitation buffer (1% Triton X-100, 150 
mM NaCl, 1 mM EDTA, 10 mM Tris pH 7.4, 1 mM EGTA pH 8.0, 0.2 mM sodium 
ortho-vanadate, 0.2 mM PMSF, 0.5% NP-40) for 30 min. Cell homogenates scraped 
from the plates were then passed 10 times through a 27 gauge needle to disperse any 
large aggregates, and centrifuged (16,000g) for 15 min to get whole cell lysates. For 
initiation of immunoprecipitation, 2 µg (10 µl) anti-RAIDD antibody was added into 
each 1.5-ml Eppendorf tube containing 1 ml whole cell lysate (total 100 µg protein) 
and incubated in constant agitation for 1 hr. Afterwards, 10 µl of 50% agarose-
immobilized Protein A was added to the mixture and incubated in agitation for 30 min. 
After centrifuging for 4 min (16,000 x g), the pellets were rinsed by cold 
immunoprecipitation buffer for 3 times and resuspended in 30 µl double-concentrated 
electrophoresis sample buffer (125 mM Tris pH 6.8, 4% SDS, 10% glycerol, 0.006% 
bromophenol blue, 2% β-mercaptoethanol). The samples were boiled and subjected to 
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electrophoresis and Western blotting for detection of RAIDD and caspase-2 as 
described below. 
2.2.10. Western blotting of tTG, caspase-2, RAIDD, cytochrome c, p53, 
p21WAF1/CIP1 and p27KIP1 
Cells cultured in dishes or multiwell plates were washed with cold PBS, scraped in a 
homogenizing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 mM 
PMSF, and 10 µg/ml each of aprotinin, leupeptin, and pepstatin) by cell-lifers, and 
sonicated on ice 3 times (10 sec each). The samples were stored at -70oC if not 
immediately used for Western-blotting. 
Some of experimental conditions for detecting tTG, caspase-2, RAIDD, p53, 
p21WAF1/CIP1 and p27KIP1 in cell homogenates by Western blotting were summarized in 
Table 3. Aliquots of samples were boiled in a loading buffer (100 mM Tris-HCl, pH 
6.8, 200 mM DTT, 20% glycerol, 4% SDS, and 0.2% bromophenol blue) for 5 min 
and centrifuged at 9,000 x g for 5 min. These samples or aforementioned 
immunoprecipitation samples were subjected to a 10% SDS-polyacrylamide gel for 
electrophoresis (SDS-PAGE) and proteins were then electro-transferred to 
nitrocellulose or polyvinylidine difluoride (PVDF) membranes. The membranes were 
blocked in TBST buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.2% Tween-
20) containing 5% dried non-fat milk (using BSA for p53) for 1 hr at room 
temperature. Subsequently, membranes were blotted with the antibodies (see Table 3 
for the details of dilution) against tTG, caspase-2, RAIDD, p53, p21WAF1/CIP1 and 
p27KIP1 for 1-2 hrs at room temperature. After three washes in TBST (5 min each), the 
membranes were incubated with horseradish peroxidase-conjugated secondary 
antibodies (anti-goat IgG, anti-rabbit IgG or anti-mouse IgG as appropriate) for 60 min  
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Table 3. Selected conditions for Western blotting of different proteins in this study 




Blocking buffer/Time (h) 1st Ab conc.
tTG 20 10 5% dried non-fat milk/1 1:1000 
Caspase-2,  20 10 5% dried non-fat milk/2 1:250 
RAIDD,  20 10 5% dried non-fat milk/1 1:1000 
Cytochrome c 20, mitochondria 40, cytosol 15 5% dried non-fat milk/2 1:1000 
p53,  20 10 5% BSA/2 1:500 
p21WAF1/CIP1  20 10 5% dried non-fat milk/2 1:500 
p27KIP1 20 10 5% dried non-fat milk/1 1:1000 
at room temperature. The membranes were washed again (3 x 15 min) in TBST. The 
light-emitting signals were detected using the enhanced chemiluminescence (ECL) 
system followed by exposure to an x-ray film. The films were scanned by desktop 
scanner and data saved as Tagged-Image File Format (TIFF) files. The optical density 
of bands on the films was semi-quantified by computer-assisted densitometry. 
For Western blotting of cytochrome c, aliquots of cytosol (40 µg protein) and 
mitochondrial lysate (20 µg protein) were subjected to 15% SDS-PAGE, and proteins 
then transferred to PVDF membranes. The membranes were blocked with dried non-
fat milk and subsequently blotted with cytochrome c antibody. Afterwards, the 
immuno-detection was performed as described above. In this study, levels of β-tubulin 
were served as loading control of Western blotting. 
2.2.11. Determination of lactate dehydrogenase (LDH) release 
Cells (0.15 x 106) were seeded in 96-well plates and cultured in normal medium for 2 
days and then in serum-free culture medium with test agents for 24 or 48 hrs. Fetal 
calf serum was excluded during the treatment periods since the medium containing 
serum exhibited unknown factors which increased the blank signal dramatically 
(equivalent to 3 times of LDH activity in HIT cell homogenates) and made it 
impossible to meaningfully measure the activity of released LDH in our samples. At 
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the end of treatment, equal amounts of supernatant from each well were mixed with 
the LDH assay solution (kits from Sigma, St. Louis, MO) and incubated for 30 min at 
37oC. The absorbance at 340 nm was measured and the LDH activity was calculated 
according to the instructions provided the kit supplier. 
2.2.12. Statistical analysis 
All data are presented as the means ± SE of the number of independent experiments. 
Statistical analysis of the data was performed by the Student's t test or one-way 
analysis of variance (ANOVA) followed by an appropriate post hoc comparison. The 
outcome of p<0.05 was considered statistically significant difference. 
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3.1. Role of tTG in GTP depletion induced apoptosis of insulin-
secreting cells 
3.1.1. Increase of in situ tTG activity and induction of apoptosis by MPA in HIT 
cells 
As demonstrated previously (Li et al., 1998; Huo et al., 2002), sustained depletion of 
GTP with MPA for 24 or 48 hrs induced apoptotic death of HIT cells as assessed by 
MTS test (Fig. 7). This convenient assay is widely used for determining the number of 
viable cells (Buttke et al., 1993; Wong et al., 2001). Our previous studies indicate this 
test is a good way to monitor apoptotic cell death once the presence of the latter has 
been formally established by more specific means such as EM and DNA-laddering (Li 
et al., 1998) and more recently by flow cytometry (Huo et al., 2002). 
The in situ tTG activity was significantly increased in parallel under the same 




























---------24 h--------- ---------48 h---------
Fig. 7. Induction of apoptosis of HIT cells 
by MPA treatment in a dose-dependent 
manner. Cell seeded on 96-well plates were 
treated with various concentrations of MPA 
for 24 or 48 hrs. Cell viability was evaluated 
by MTS test (formazan production). Data 
are mean ± SEM of 4 independent 
experiments. * P<0.05 and ** P<0.01 vs.
control.
 


























Figure 8. Increase of in situ tTG activity by 
GTP-depletion after MPA treatment in a 
dose-dependent manner. Cell seeded on 96-
well plates were treated with various 
concentrations of MPA for 24 or 48 hrs. In situ
tTG activity was measured by a streptavidin-
linked enzyme assay detecting the formation of 
a tTG-dependent product from a loaded 
substrate. Values are mean ± SEM of 3 
independent experiments. * P<0.05 and ** 
P<0.01 vs. control.
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activity was increased by 33% after treatment of 24 hrs and increased further (+133%) 
after 48 hrs. The two effects of MPA (promotion of cell death and enhancement of 
tTG activity) were closely correlated in a dose-dependent manner (Fig. 9). 
Furthermore, data in Fig. 9 demonstrated that both actions were prevented by the 
provision of guanosine (which restores GTP content and GTP/GDP ratio) but not by 
adenosine (which restores any possible reduction in ATP content) (Metz et al., 1992; 
Meredith et al., 1997; Li et al., 2000), indicating that the enhanced tTG activity, 
similar to the induction of apoptosis, in MPA-treated cells is due specifically to the 
depletion of GNs.  
The increased tTG activity during MPA treatment could result from elevated tTG mass 
and/or stimulation of enzyme activity. To address this question, we evaluated tTG 
protein levels by Western blotting. Surprisingly, MPA treatment did not enhance tTG 
mass but rather moderately decreased its levels at higher concentrations (Fig. 10), 
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Fig. 9. Prevention of MPA-promoted 
increase of in situ tTG activity (A) and 
induction of cell death (B) by the 
provision of guanosine but not 
adenosine. HIT cells in 96-well plates 
were cultured with a series concentrations 
of MPA for 48 hrs. Guanosine (500 µM) 
or adenosine (500 µM) was also included 
upon appropriate. Cell viability was 
evaluated by MTS test (formazan
production) and in situ tTG activity was 
measured by the formation of product 
from a loaded substrate for the enzyme. 
Data are mean ± SE of 4 independent 
experiments. * P<0.05 and ** P<0.01 vs.
control.
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and/or degradation. Neither tTG degradation products nor its polymers could be 
detected in our studies (data not shown). The decrease of tTG mass was not observed 
at an early time point (24-h) but was visible after 48-h MPA treatment. Possibly, MPA 
might induce tTG secretion from HIT cells. This MPA-induced alteration in tTG mass 
was also blocked by addition of guanosine but not adenosine (Fig. 10). Thus the 
increase of tTG activity in GTP-depleted β-cells was due to the activation of the 
enzyme per se rather than an increase of its mass. 
MPA (µg/ml) 0     0.1    0.3    1      3      10     10    10
Guanosine    - - - - - - +      -















Fig. 10. Decrease of tTG expression at protein 
level after 48-h MPA treatment. tTG was 
determined by Western-blotting followed by 
densitometry analysis. The effect of MPA on 
decrement of tTG mass was blocked by 
inclusion of guanosine (500 µM) but not 
adenosine (500 µM). The blotting is the 
representative of 4 independent experiments 
under the same conditions. Bar values are mean 
± SE from density analysis of these 
experiments. * P<0.05 vs. control.
 
3.1.2. Effects of tTG inhibitors on tTG activity and apoptosis during MPA 
treatment 
The relationship between increased tTG activity and apoptotic cell death during GTP-
depletion by MAP was studied under condition of tTG inhibition. In one series of 
experiments, two tTG inhibitors, monodansylcadaverine (MDC) or putrescine (Tsai et 
al., 1998), were co-cultured together with 3 µg/ml MPA for 48 hrs. The inhibitors had 
no apparent effect on cell viability and proliferation under basal conditions by 
themselves at the doses used in our study. In contrast, either 100 µM MDC or 6.25 
mM putrescine was able to block the in situ tTG activity by almost half (42-43%) (Fig. 
11A). However, they did not rescue the cells from apoptosis under the same conditions 
(Fig. 11B). In addition, the tTG inhibitors did not alter tTG mass during MPA 
treatment as assessed by Western-blotting (data not shown). 
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Fig. 11. Partial suppression of MPA-
enhanced tTG activity (A) but failure of 
prevention of MPA-induced apoptosis 
(B) by two tTG inhibitors. HIT cells 
were treated with 3 µg/ml MPA alone or 
combined with 100 µM MDC or 6.25 mM 
putrescine in culture media for 48 hrs. Cell 
viability was evaluated by MTS test 
(formazan production) and in situ tTG
activity was measured by a streptavidin-
linked enzyme assay. Data are mean ± SE 
of 6 independent experiments. ** P<0.01 
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In another series of experiments, free Ca2+ levels in culture medium were lowered to 
80-120 nM by using the Ca2+ chelator EGTA, since tTG activity is not only regulated 
by GTP (suppression) but is also stimulated by Ca2+ (Smethurst and Griffin, 1996; 
Zhang et al., 1998; Melino and Piacentini, 1998). The results revealed that lowering of 
extracellular free Ca2+ levels almost abolished (by 91%) the enhanced tTG activity due 
to MPA (Fig. 12A), but failed to prevent cell death triggered by GTP depletion (Fig. 
12B). Lowing free Ca2+ levels to 80-120 nM itself did not damage cell viability.  
In addition, MPA-induced apoptosis was also examined by flow cytometry which 
determines the subdiploidy apoptosis (sub-G1 phase) due to DNA fragmentation (Huo 
et al., 2002). As shown in Table 4, 53% cells were detected undergoing apoptotic 
death after MPA treatment (3 µg/ml for 48 hrs). Putrescine, MDC and lowing free 
Ca2+ did not affect cell viability by themselves. In agreement with the results from 
MTS test (Fig. 11B), neither putrescine nor MDC was able to rescue the cells from 
MPA-induced cell apoptosis (Table 4). However, lowing free Ca2+ was able to slightly  
 Chapter 3 Results 
  52
Fig. 12. Significant suppression of MPA-
enhanced tTG activity by EGTA without 
prevention of MPA-induced apoptosis. 
HIT cells in 24-well plates were cultured 
with 3 µg/ml MPA for 48 hrs. The Ca2+
chelator EGTA (0.83 mM) was also included 
where appropriate. tTG activity (A) was 
measured by the formation a product from a 
loaded substrate for the enzyme and cell 
viability (B) was evaluated by MTS test. 
Values are mean ± SEM of 5 independent 
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(by 29%) but significantly relieve MPA-evoked cell death. These data suggested that 
while tTG might have some small involvement, it appeared not to play a major role in 
the induction of apoptosis due to GTP-depletion. 
Table 4. Analysis of MPA-induced 
subdiploidy apoptosis by flow 
cytometry. HIT-cells in 6-well 
plates were cultured under the above 
conditions for 48 hrs. All cells were 
collected and stained by propidium
iodide and subject to flow 
cytometric analysis as detailed in the 
Methods and Materials section. The 
cells in sub-G1 phase whose DNA 
were fragmented were counted as 
subdiploidy apoptosis. Values are 
mean ± SEM from 3-7 independent 
experiments. * p<0.05 and ** 
p<0.01 vs. MPA alone12.2 ± 1.7**MPA + 200 µM Z-VAD-FMK
13.9 ± 2.0**MPA + 100 µM Z-VAD-FMK
42.3 ± 1.8*MPA + Lowering free Ca2+
51.3 ± 1.9MPA + MDC
54.3 ± 6.1MPA + Putrescine
10.7 ± 3.3Lowering free Ca2+
8.7 ± 2.6MDC, 100 µM
11.4 ± 3.2Putrescine, 6.25 mM
53.2 ± 2.7MPA, 3 µg/ml
8.4 ± 1.3Control
Apoptotic cells (%)Condition
3.1.3. Effects of caspase inhibitor on tTG activity in GTP depletion 
It is well established that caspase activation is involved in both initiation and 
execution of apoptosis (Green and Reed, 1998; Budihardjo et al., 1999). To study 
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whether the increased tTG activity during GTP-depletion by MPA is related to caspase 
activation, a cell-permeable pan-caspase inhibitor, Z-VAD-FMK (Gamen et al., 1997; 
Bras et al., 1999), was employed. This peptide derivative is able to bind specifically to 
general caspases but the modification of its C-terminal aspartic acid with fluoromethyl 
ketone (FMK) renders it an irreversible caspase inhibitor rather a substrate (Talanian 
et al., 1997). At 100 µM, Z-VAD-FMK completely prevented apoptosis induced by 
GTP-depletion as assessed by MTS test (Fig. 13A) as well as the accompanying 
activation of several caspases (Huo et al., 2002). Similarly, MPA-induced apoptosis 
was prevented by the caspase inhibitor as determined by flow cytometry (Table 4). 
However, the same concentration, or an even higher one (200 µM), of the pan-caspase 
inhibitor did not prevent the increase of in situ tTG activity caused by MPA treatment 
(Fig. 13B). This suggested that the enhanced tTG activity occurs either up-stream or 
independent of caspase activation during MPA-treatment. 
Fig. 13. Prevention by a pan-
caspase inhibitor of apoptosis but 
not the increased tTG activity 
induced by MPA. HIT cells in 
multi-well plates were cultured with 
3 µg/ml MPA for 48 hrs and the pan-
caspase inhibitor Z-VAD-FMK (100 
or 200 µM) was also included upon 
appropriate. Cell viability was 
evaluated by MTS test (A) and in situ
tTG activity was measured by a 
streptavidin-linked enzyme assay (B). 
Data are mean ± SEM of 3 
independent experiments. ** P<0.01 
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3.1.4. tTG activity and cell morphology 
Control HIT cells grew in clusters on culture plates and the cell boundary was 
ambiguous (Fig. 14A). MPA treatment caused the cells to round up and individual 
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cells became recognizable (Fig. 14B). In addition, many of these cells lost their normal 
brightness. Guanosine, which abolished MPA-induced tTG activation (Fig. 9), 
restored normal morphology (Fig. 14C) while adenosine had no such effect (Fig. 
14D). However, the morphological changes induced by MPA treatment could only be 
marginally reversed by the pan-caspase inhibitor (Fig. 14E-F), allowing for a possible 
role of tTG in this process compatible with its proposed role in protein cross- 
 
Fig. 14. Partial prevention of MPA-
induced morphological alterations by tTG
inhibitors. HIT cells in coverslip chambers 
were cultured for 48 hrs in the following 
conditions: control (A); 3 µg/ml MPA (B); 
MPA plus 500 µM guanosine (C); MPA plus 
500 µM adenosine (D); MPA plus 100 µM 
(E) or 200 µM (F) Z-VAD-FMK; MPA plus 
6.25 mM putrescine (G) or 100 µM MDC 
(I); MPA plus putrescine and 100 µM Z-
VAD-FMK (H); and MPA plus putrescine
and 100 µM Z-VAD-FMK (J). Cell 
morphology was examined under differential 
interference contrast (DIC) by microscopy. 
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linking (Fesus and Thomazy, 1988; Greenberg et al., 1991; Fesus, 1998; Melino and 
Piacentini, 1998). Indeed, either putrescine or MDC was able to markedly prevent the  
morphological changes in MPA-treated cells (Fig. 14G, 14I) and this effect was more 
apparent in the presence of a caspase inhibitor (Fig. 14H, 14J); these observations 
matched the observation that they could only produce incomplete inhibition of MPA-
induced tTG activation (cf. Fig. 11A). 
It has been proposed that an effect of tTG is to stabilize dying cells by polymerization 
of substrate proteins (Fesus, 1998; Melino and Piacentini, 1998). Cross-linking of 
proteins by tTG might reduce the release of cytoplasmic materials from cells 
undergoing apoptosis and inhibition on tTG therefore might increase the release in 
apoptotic cells. In order to address this issue, we assessed LDH release from MPA-
treated cells under various conditions (Fig. 15). There was no apparent release of LDH 
after 24-h treatment with MPA, whereas 48-h exposure to MPA caused an increase of 
LDH release by 191%. Neither a combination of two tTG inhibitors (MDC and 
putrescine) nor lowing Ca2+ by EGTA affected the MPA-induced LDH release. 
However, the pan-caspase inhibitor (Z-VAD-FMK) prevented the MPA-induced LDH 
release and also the increase in fragmented DNA measured by flow cytometry (cf. Fig.  
 
Fig. 15. LDH release from HIT cells after 
MPA treatment under various conditions.
After HIT cells seeded in 96-well plates were 
treated with test agents in culture medium for 24 
or 48 hrs, the LDH activity in the supernatants 
was measured as described in the Materials and 
Methods. Values are mean ± SEM of 5 
independent experiments. * P<0.01 vs. MPA 
treatment alone. The final concentrations during 
treatment were: MPA, 3 mg/ml; MDC, 100 μM; 
putrescine, 6.25 mM; EGTA, 0.83 mM; and Z-
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13A and Table 4). As expected, inclusion of tTG inhibitors did not significantly alter 
the reversing effect by Z-VAD-FMK on LDH leakage. These data support our 
conclusion that tTG does not play a major role in the phenomena associated with 
apoptosis, including leakage of cytoplasmic contents 
3.1.5. Section summary 
This part of work attempted to delineate the role of tTG in apoptosis of insulin-
secreting HIT-T15 cells induced by GTP depletion with MPA. The results showed that 
GTP depletion elevated tTG activity. The time course and dose-response of this effect 
was in close relationship with apoptosis induction. The elevated enzyme activity was 
not due to an increase of its mass. Provision of guanosine completely prevented MPA-
induced cell death and increase of tTG activity. Although tTG inhibitors and lowering 
of Ca2+ were able to suppress tTG activation, MPA-induced cell death was not or only 
slightly relieved under these conditions. A general caspase inhibitor was capable of 
preventing MPA induced apoptosis without affecting the tTG activation, indicating 
that GTP depletion can provoke the two events either independently or one after 
another. Importantly, the morphological changes accompanying apoptosis could be 
partially prevented by tTG inhibitors. These findings suggest that the effect of the 
marked increase in tTG activity during GTP-depletion induced apoptosis of insulin-
secreting cells may be restricted to some terminal morphological alterations.  
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3.2. Importance of activation of caspases for the apoptosis induced by 
GTP-depletion in insulin-secreting cells 
3.2.1. Induction of apoptosis by GTP depletion with MPA treatment  
HIT cells were treated with 3 µg/ml MPA for up to 48 hrs. Flow cytometric analysis of 
PI-stained cells indicated that MPA induced cell arrest in G1 (diploid peak) phase 
(Fig. 16A and Table 5). The cells at S and G2/M phases were significantly reduced 
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Figure 16. Time-course of cell death 
induced by MPA treatment. HIT cells 
seeded on multi-well plates were treated 
by MPA (3 µg/ml) in culture media for 
up to 48 hrs. (A), Cells were stained with 
PI and subject to flow cytometric analysis 
of MPA effects on cell growth/death. The 
graph is a typical representative of 3 
independent experiments. The cells 
whose DNA content was lower than G1 
phase contained fragmented nuclei and 
were undergoing apoptosis. (B), 
Percentages of MPA-induced subdiploidy
apoptotic cells analyzed by flow 
cytometry. Values are mean ± SE from 3 
independent experiments. (C), Cell 
viability was evaluated both by formazan
production in MTS test and by 
determination of DNA content in the 
wells under different conditions. 
Corrections were made for the influence 
of a slight increase (15-20% during 48 
hrs) in the cell number of control wells in 
all data (both MTS test and DNA content) 
at indicated time points. Values are mean 
± SE from 7 independent experiments. * 
P<0.05 and ** P<0.01 vs. zero time point. 
 
 Chapter 3 Results 
  58
cells with fragmented nuclei; the DNA content of these cells was lower than that at G1 
phase (in sub-G1 fraction) (Fig. 16A and Table 5). These subdiploid cells with 
fragmented nuclei thus were undergoing apoptosis (Nicoletti et al., 1991). This 
apoptotic effect of MPA was time-dependent and occurred significantly after 24-h 
treatment with MPA (Fig. 16B), confirming our previous findings obtained using 
different methods (Li et al., 1998). 
5.1 ± 0.6 **3.2 ± 0.4 **47.6 ± 2.1 **44.7 ± 2.8 **48
5.5 ± 1.1 **3.4 ± 0.3 **56.7 ± 2.0 *34.2 ± 3.0 **40
5.6 ±0.2 **4.8 ± 0.1 **77.8 ± 0.1 12.3 ±0.2 **32
7.7 ± 1.0 **6.6 ± 0.3 **74.3 ± 0.7 11.4 ± 1.5 *24
9.1 ± 0.4 **9.2 ± 0.6*74.5 ± 2.4 5.8 ± 0.5 16
11.2 ± 0.2 10.5 ± 0.2 74.6 ± 0.5 5.5 ± 0.8 8
13.5 ± 0.5 11.0 ± 0.3 72.4 ± 1.6 4.7 ± 0.4 0
G2/MSG1Sub-G1Treatment time (h)
Fractions Table 5. Effects of MPA treatment on 
cell cycle of HIT cells. HIT cells in 6-
well plates were treated with 3 µg/ml 
MPA for indicated time periods. After 
one gentle rinse, cells were detached by 
trypsinization and stained with 
propidium iodide and subject to flow 
cytometric analysis. Data are expressed 
as % of total cells (10,000) analyzed. 
Values are mean ± SE from 3 
experiments in triplicate. * P<0.05 and 
** P<0.01 vs. zero time point.
 
Cell viability was also assessed by MTS test and DNA content [changes in which were 
correlated with other typical markers of apoptosis induced by GN-depletion (Li et al., 
1998)] every 8 hrs during treatment. MPA led to a dose-dependent decrease of both 
formazan production (MTS test) and DNA content (data not shown). The time-courses 
of alterations of these two parameters following MPA treatment of HIT cells were 
generally parallel, although the decease in DNA occurred slightly before the drop in 
MTS signal (Fig. 16C), possibly because GTP reduction directly inhibits DNA 
synthesis (Li et al., 1998; Metz et al., 2001). Significant reductions (-15%, P<0.01) of 
DNA were observed at 24-hr treatment, a time point when clear apoptotic alterations 
(chromosome condensation/fragmentation, DNA laddering) occurred (Li et al., 1998). 
Both formazan production and DNA content were decreased by about 60% after 48-hr 
exposure to the GN-depleting agent. The time course of changes in MTS test and 
DNA content after MPA treatment was correlated with the percentage of apoptotic 
cells (Fig. 16B) as assessed by flow cytometry under the same conditions. 
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3.2.2. Activation of caspases and release of cytochrome c by MPA treatment 
The activity of caspase-1 through caspase-10 in HIT cells after MPA treatment was 
measured by using their respective, specific substrates (Talanian et al., 1997) (Fig. 17). 
Six such synthetic oligopeptide substrates were used: Ac-WEHD-AFC for caspase-1, -
4, and -5; Ac-VDVAD-AFC for caspase-2; Ac-DEVD-AFC for caspase-3, -7 and -10; 
Ac-VEID-AFC for caspase-6; Ac-LETD-AFC for caspase-8; and Ac-LEHD-AFC for 
caspase-9. Cell homogenates were prepared after MPA treatment (3 µg/ml) at various 
time intervals. Activity of several caspases was increased subsequent to sustained GN-
depletion. Caspase-2 was clearly activated at 16 hrs, earlier than other caspases and 
prior to the onset of apoptosis, and maximal activity (+343%) was seen at 32 hrs, prior  
Figure 17. Activity of caspases in HIT cells during MPA treatment. Cells seeded 
in 6-well plates were treated with 3 µg/ml MPA in culture media for 8-48 hrs. Cell 
homogenates were prepared as described in detail in the Methods section. Caspase
activity was determined by measurement of the cleavage of the fluorogenic, specific 
substrates. Values are mean ± SE from at least 4 independent experiments. * P<0.05 
and ** P<0.01 vs. control
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to the maximal levels of apoptosis achieved. In another study measuring caspase-2 
activity in shorter intervals (every 2 hrs) during MPA treatment (0-12 hrs), the 
protease activity was significantly increased by 105% (n=3; P<0.001) at 12 hrs. 
Caspase-3 (and perhaps also -7 and -10) and caspase-9 were only activated at 24 hrs  
MPA treatment and their activity was increased maximally by 145% and 150% 
respectively at 32 hrs (Fig. 17). 
Caspase-2 activation was also confirmed by detection of its cleavage (Li et al., 1997b) 
by Western blotting (Fig. 18). Soane et al reported that caspase-2 is activated by 
cleavage first into three fragments of 32-33 kDa and 14 kDa, thereafter, further 
processed into 18- and 12-kDa active subunits (Soane et al., 1999). Generally 
speaking, 32-33 kDa cleavage means caspase-2 activation. Inactivated caspase-2 in 
control HIT cells displayed a band of 48 kDa on the SDS-polyacrylamide gel. This 
caspase isoform was dominantly present in cytosol and faintly detected in 
mitochondria (Fig. 18A). The 48-kDa inactive caspase-2 in cytosol was slightly 
elevated with the time of culture both in control and MPA-treated cells. After MPA 
treatment, a band of 35 kDa in cytosol appeared at 16 hrs and reached maximal at 32   
 
Figure 18. Cleavage of caspase-2 by MPA 
treatment and interaction of RAIDD with 
caspase-2. (A and B) HIT cells were treated with 3 
µg/ml MPA for 8-48 hrs. Cell lysates were subjected 
to 10% SDS-PAGE and caspase-2 cleavage was 
detected by immunoblotting using an antibody 
reacting with both the enzyme (48 kDa) and its large 
cleavage product (35 kDa). No difference in the β-
tubulin content (loading control) was found between 
samples. The results were the representative of 5 
independent experiments. (C) HIT cell homogenates 
(100 µg protein each) were incubated with anti-
RAIDD antibody followed by addition of agarose-
immobilized Protein A. After washing and 
centrifuging, the immunoprecipitation pellets were 
resuspended in electrophoresis buffer and boiled. 
The samples were subject to electrophoresis and 
Western blotting for detection of RAIDD and 
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pulled down together with RAIDD (Fig. 18C). Moreover, MPA treatment slightly 
reduced the amount (a decease of about 20 %; P<0.05; n=4) of caspase-2 (inactive 
form) co-precipitated with RAIDD. 
Caspase-9 can be activated by cytochrome c (Li et al., 1997b; Green and Reed, 1998), 
therefore, it is possible that GN-depletion by MPA treatment is capable of causing the 
release of cytochrome c from mitochondria into cytosol. This was shown to be true, 
since cytochrome c in cytosol was increased while that in the mitochondria fraction 
was decreased in MPA-treated HIT cells (Fig. 19). By analyzing the data from 
Western blotting with densitometry, the cytochrome c content in cytosol was elevated 
by 57% (P<0.05) at 24-hr, and 69% and 174% (both P<0.01) after 32 and 48 hrs in 
corresponding to 18% (P<0.05) and 61% (P<0.01) reduction of its content in 
mitochondria. No significant release was observed at 8- and 16-hr treatment. Thus 
these changes occurred after increase in active caspase-2 but before apoptotic changes 
(Fig. 16). 
Figure 19. Release of cytochrome c from 
mitochondria into cytosol during MPA 
treatment. HIT cells were treated with 3 µg/ml 
MPA for the indicated periods. Mitochondria 
fraction and cytosol were obtained by 
subcellular fractionation. They were subjected to 
15% SDS-PAGE and cytochrome c was 
determined by immunoblotting. There was no 
difference in the β-tubulin content between 
samples. The results were the representative of 4 
independent experiments
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There was no apparent increase in the activity of caspase-1, -4, -5, -6 and -8 during 
MPA treatment (Fig. 17). 
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3.2.3. Blockade of MPA-induced apoptosis by caspase inhibitors  
Although GN-depletion activates several caspases, it was unclear whether the latter 
mediate entirely the apoptosis seen under the same conditions, in view of the reports 
that apoptosis could occur without involvement of caspases (Borner and Monney, 
1999; Lorenzo et al., 1999). Therefore, caspase inhibitors were used to address this 
question. All cell-permeable caspase inhibitors (10 mM stock solution prepared in 
DMSO) used below were non-toxic and had no effects on both MTS test and DNA 
content in HIT cells by themselves under the concentrations applied. A pan-caspase 
inhibitor, Z-VAD-FMK that suppresses a broad range of the enzymes in the group 
(MacFarlane et al., 1997) was first used to examine its effects on GN-depletion 
induced cell death at various concentrations and at different time of treatment (Fig. 
20). The decreases in both formazan production (MTS test) and DNA content due to 
48-hr MPA treatment were attenuated by 10 µM and were completely restored to 
normal by 100 µM of the inhibitor (Fig. 20A). When Z-VAD-FMK (100 µM) was 
added together with MPA to the cells for various periods, the changes both in 
formazan production (Fig. 20B) and DNA content (Fig. 20C) by GN-depletion was 
completely blocked at all examined time points. 
It is possible that the protective effect of caspase inhibitors on GN-depletion induced 
apoptosis was mediated via an action on restoration of cellular levels of GTP. The 
results from 2 series of experiments, however, are against this notion. First, the pan-
caspase inhibitor (Z-VAD-FMK, 100 µM) was unable to reverse the inhibition of 
stimulated insulin secretion in HIT cells treated with MPA for 6 hours (data not 
shown), a time when levels of GTP are reduced by > 80% (Meredith et al., 1997; Li et 
al., 2000). By contrast, addition of guanosine was able to restore the GN levels and 
also reverse the inhibitory effect of MPA on insulin secretion (Meredith et al., 1997; 
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Li et al., 2000). Second, GN-depletion by MPA activated tissue transglutaminase in 
HIT cells in a dose- and time-dependent manner (Fig. 8 and Fig. 9). This 
transglutaminase is an enzyme whose activity is suppressed by mM levels of GTP and 
may be involved in apoptotic process, in particular the morphological changes. We 
found that the pan-caspase inhibitor was able to reverse MPA-induced apoptosis, but 
failed to block the MPA-enhanced tTG activity (Fig. 13). However, co-treatment with 
guanosine could block both MPA-induced apoptosis and activation of tTG. Therefore, 
our results clearly indicate that reversal of GN-depletion induced HIT cell death by 
caspase inhibitors is not trivially due to prevention of the GTP reduction. 
Figure 20. Blockade of GN-depletion 
induced cell death by a pan-caspase
inhibitor. HIT cells in multi-well plates 
were treated with MPA (3 µg/ml) in the 
presence or absence of a pan-caspase
inhibitor (Z-VAD-FMK) in culture media 
for various periods. Cell death was 
assessed by both MTS test and the 
determination of DNA content in the 
wells. Values are means ± SE of at least 3 
independent experiments. (A), Dose-
dependent prevention of GN-depletion 
induced apoptosis by Z-VAD-FMK at 48 
hrs of MPA treatment; (B) and (C), time-
course of the protective effects of the 
pan-caspase inhibitor (100 µM) on cell 
viability monitored by MTS test and the 
DNA content. Values are mean ± SE 
from 4-5 independent experiments. * 
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To define whether a particular caspase(s) plays the critical role in GN-depletion 
induced apoptosis, specific caspase inhibitors were also used. The caspase-2 inhibitor, 
Z-VDVAD-FMK (Talanian et al., 1997; Li et al., 1997a; Chen et al., 1999) protected 
the cells from death due to MPA treatment (Fig. 21). At 100 µM, the caspase-2 
inhibitor restored the formazan production almost completely to control values, similar 
to the action by the pan-caspase inhibitor described above. In addition, the reduction 
of DNA content could be restored to >80% of control by the caspase-2 inhibitor (this 
residual reduction, which was still significantly lower than control, may be due to 
direct inhibition of DNA synthesis by GTP depletion; see above). On the contrary, the 
caspase-3 inhibitor, DEVD-CHO (100 µM) that blocks apoptosis in other cell types  
Figure 21. Blockade of GN-depletion 
induced cell death by a specific 
caspase-2 inhibitor. HIT cells grown in 
multi-well plates were treated with MPA 
(3 µg/ml) in the presence or absence of a 
specific caspase-2 inhibitor (31) (Z-
VDVAD-FMK) for various periods. 
Apoptosis was monitored by both MTS 
test and the determination of DNA 
content. Results are means ± SE of at 
least 4 independent experiments. (A), 
Dose-dependent blockade of GN-
depletion induced apoptosis by Z-
VDVAD-FMK at 48 hrs of MPA 
treatment; (B) and (C), time-course of the 
effects of the caspase-2 inhibitor (100 
µM) on cell viability assessed by MTS 
test and the DNA content. Values are 
mean ± SE from 3-4 independent 
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(Banki et al., 1999; Soane et al., 1999), was only able to partially restore DNA content 
by 35% and did not restore the cell viability at all during 48-hr MPA treatment (Fig. 
22). The caspase-3 inhibitor also failed to reverse the morphological changes due to 
MPA (data not shown). These findings by using caspase inhibitors suggest that, 
lthough activated caspase-3 is partially responsible for only the DNA degradation, 
caspase-2 is a major mediator in the induction of apoptotic death of insulin-secreting 
cells induced by GN-depletion. 
 
Figure 22. Partial prevention by a caspase-3 
inhibitor of reduction of DNA content induced 
by GN-depletion; comparison to absence of 
effect on cell viability (MTS test). HIT cells 
were treated with 3 µg/ml MPA and a caspase-3 
inhibitor (DEVD-CHO, 100 µM) for 48 hrs. 
Results are means ± SE of 3 independent 


















3.2.4. Section summary 
This study investigated the involvement of caspases in GTP-depletion induced 
apoptosis of β-cells. GTP depletion by MPA treatment reduced cell cycle progress 
from G1 phase into S and G2/M phases. In addition, activation of several caspases 
occurred in the process. However, the predominant one with increase in activity is 
caspase-2 and its activation preceded that of other caspases and, significantly, precedes 
the appearance of apoptosis. Furthermore, a pan caspase inhibitor and also a specific 
caspase-2 inhibitor (but not a caspase-3 inhibitor) were able to prevent MPA-induced 
apoptosis. Release of mitochondrial cytochrome c into cytosol and activation of 
caspase-9 and -3 seems to be down-stream or secondary to caspase-2 activation. These 
data indicate that activation of caspase-2 mediates the initiation of apoptosis of 
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pancreatic β cells subsequent to mitogenesis inhibition due to sustained GTP 
depletion. 
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3.3. Role of cell cycle regulators in the activation of caspases and 
induction of apoptosis in β-cells due to GTP-depletion  
We have demonstrated above that MPA arrests HIT-T15 cells at G1 phase and triggers 
caspase-dependent apoptosis in which caspase-2 plays a major role. It appears that a 
causal relationship between inhibition of mitogenesis and activation of 
caspases/induction of apoptosis over sustained GTP depletion by MPA may exist. At 
least two lines of evidence suggest this possibility. First, MPA might affect p53 
expression because IMPDH, the specific target of MPA, may interact with p53 
(Sherley, 1991; Xu et al., 1998). p53 is an important regulator of cell growth and 
apoptosis (Vousden et al., 2002). Second, CDK inhibitors, such as p27KIP1 and 
p21WAF1/CIP1, play important roles in the regulation of cell cycle progress from G1 
phase into S phase (Xiong et al., 1993; Deng et al., 1995; Bissonnette and Hunting, 
1998). Our earlier study found that MPA inhibited this transition of cell cycle. It is 
thus possible that the expression of these proteins may be altered by GN-depletion, 
resulting in inhibition of mitogenesis and activation of caspases. Consequently, the 
levels of three cell cycle regulators, p53, p27KIP1 and p21WAF1/CIP1, were examined in 
the course of induction of apoptosis by GTP depletion with MPA. 
3.3.1. Increment of p21WAF1/CIP1  by MPA treatment  
GTP depletion by MPA treatment significantly increased p21WAF1/CIP1 (Fig. 23A); its 
mass was elevated by 23%, 74%, 159%, 220% and 94% following 8, 16, 24, 32, and 
40 hrs of MPA (3 µg/ml) treatment, respectively. Furthermore, the pattern of time-
course of p21WAF1/CIP1 induction was closely correlated with that of caspase activation 
(Fig. 23B) occurring under the same conditions. Both events were significantly 
apparent at 16 hrs and reached maximal effects at 32 hrs of MPA exposure. These 
findings suggest that an increase in p21WAF1/CIP1 expression may be involved in 
caspase activation. 
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Fig. 23. Close correlation of time-response 
between the increment of p21Waf1/Cip1 mass 
(A) and activation of caspases (B) in MPA 
treated HIT-T15 cells. (A), Cells in culture 
were treated with 3 µg/ml MPA for 0-48 hrs. 
At the indicated time points, cell lysates were 
prepared as described in "Materials and 
Methods". Equal amounts of lysates (20 µg 
protein extracts) were subject to SDS-PAGE 
and blotted with an antibody against 
p21Waf1/Cip1. The mass of p21Waf1/Cip1 was 
quantified by computer-assisted densitometry. 
(B), Cells seeded in 6-well plates were treated 
with 3 µg/ml MPA in culture media for 8-48 
hrs. Caspase activity in cell homogenates were 
determined by measurement of the cleavage 
of the fluorogenic, specific substrates as 
described in details in the Methods section. 
Values are means ± SEM of eight (in A) and 
at least four (in B) independent experiments. * 
p<0.05 and ** p<0.01 vs. zero time-point (in 
A) and vs. control (0 µg/ml MPA) (in B).
Control
MPA 
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3.3.2. Reduction of p53 and p27KIP1 during MPA treatment  
Transcription of the p21WAF1/CIP1 gene can be activated by both p53-dependent and-
independent mechanisms (El Deiry et al., 1993; El Deiry et al., 1994; Agarwal et al., 
1995; Gartel et al., 1996; Alpan and Pardee, 1996). Thus we next examined the p53 
profile under the conditions when MPA caused an increase of p21WAF1/CIP1. Our results 
revealed that the levels of p53 protein in HIT cells were progressively decreased with 
the treatment time of MPA (10 µg/ml) (Fig. 24A). After exposure to MPA for 8, 16, 
24, 32, 40 and 48 hrs, p53 was reduced by 5%, 11%, 25%, 28%, 34% and 58%, 
respectively. In addition, this effect occurred in a dose-dependent manner (Fig. 24B).  
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Fig. 24. Reduction of p53 protein by MPA 
treatment. HIT-T15 cells were cultured in 
RPMI medium containing 10 µg/ml MPA for 
0-48 hrs (A) or different concentrations of 
MPA for 48 hrs (B). When present, 0.5 mM
guanosine or adenosine was also included. Cell 
lysates were prepared and subject to SDS-
PAGE (20 µg protein each) for separation. 
Western blotting was performed by blotting 
the membranes with the sheep polyclonal, 
peroxidase-conjugated antibody specific for 
wild p53. The blots were analyzed by 
computer-assisted densitometry. Values are 
means ± SEM of five (in A) and four (in B) 
independent experiments. * p<0.05, ** p<0.01 
vs. zero hour point (in A) and vs. control (0 
µg/ml MPA) (in B). 
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Figure 24. Reduction of p53 protein by MPA treatment 
After MPA treatment for 48 hrs, the mass of p53 was significantly decrease by 37% 
and 64% at 3 and 10 µg/ml, respectively. Co-culture with guanosine (500 µM), but not 
with adenosine (500 µM), entirely reversed the p53 reduction due to GN depletion by 
MPA. These observations indicate that the increase of p21WAF1/CIP1 by GN-depletion 
due to MPA treatment in HIT cells is achieved via a mechanism independent of p53. 
p27KIP1 is another important CKI regulating the progression through G1 and the G1/S 
transition (Toyoshima and Hunter, 1994; Polyak et al., 1994). MPA treatment caused 
progressive decreases of the mass of p27KIP1 (Fig. 25), in contrast to the increase of 
p21WAF1/CIP1 (cf. Fig. 23). After treatment of 16, 24, 32, 40 and 48 hrs with 3 µg/ml 
MPA, p27KIP1 levels declined by 34%, 55%, 72%, 74% and 75%, respectively (Fig. 
25A). This declining effect was also dose-dependent with significant reduction by 
41%, 61% and 68% following 48-h treatment at 1, 3 and 10 µg/ml MPA, respectively 
(Fig. 25B). Thus there is a drop in both p53 and p27KIP1 after GN depletion, while the 
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Fig. 25. Decrement of p27KIP1 by exposure to 
MPA in a time- and dose-dependent manner.
HIT-T15 cells were treated with 3 µg/ml MPA 
for 0-48 hrs (A) or 0-10 µg/ml MPA for 48 hrs 
(B). Cell lysates (20 µg protein each) were 
subject to SDS-PAGE and Western blotting 
was performed by using the goat polyclonal 
antibody against p27KIP1. The blots were 
analyzed by computer-assisted densitometry. 
Values are means ± SEM of three (A and B) 
independent experiments. * p<0.05, ** p<0.01 
vs. zero hour point (in A) and vs. control (0 
µg/ml MPA) (in B).
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Figure 25. Decrement of p27KIP1 by exposure to MPA in a time- and dose-dependent manner.  
latter is a bit more sensitive [occurring at earlier treatment time (32 hrs) and at lower 
concentrations of MPA (1 µg/ml)]. 
Interestingly, these MPA effects on p53 and p27KIP1 could not be reversed by co-
treatment with either a general caspase inhibitor (Z-VAD-FMK) or a specific caspase-
2 inhibitor (Z-VDVAD-FMK) (Fig. 26), although both caspase inhibitors are able to 
Fig. 26. No restorative effect by 
caspase inhibitors on MPA-induced 
reduction of p53 and p27KIP1. HIT cells 
were treated with 10 µg/ml (for p53) or 
3 µg/ml (for p27KIP1) MPA in the 
presence or absence of a pan-caspase
inhibitor (Z-VAD-FMK) or a caspase-2 
inhibitor (Z-VDVAD-FMK) in culture 
for 32 hrs. See legends to Fig. 24 and 25 
for other experimental details. Values 
are means of ± SEM of four (for p53) 
and ten (for p27KIP1) independent 
experiments. 
MPA - +            +           +
Z-VAD - - +           -
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block the apoptosis triggered by MPA treatment (cf. Fig. 20 and Fig. 21 ). These 
results indicate that GN-depletion by MPA causes decreases of p53 and p27KIP1 
independent of caspase(s) activation. Since both p53 and p27KIP1 were not increased 
but rather decreased after MPA treatment in a dose- and time-dependent manner, they 
may not play a major role in the inhibition of mitogenesis due to GN depletion. 
3.3.3. Induction of p21WAF1/CIP1 and caspase activation 
Our above results demonstrated that GTP depletion by MPA induced p21WAF1/CIP1 
increase in close correlation with caspase activation in a p53-independent mechanism. 
It is known that p21WAF1/CIP1 can serve as a critical checkpoint regulator for both cell 
cycle arrest and apoptosis (Gervais et al., 1998; Chai et al., 2000). Thus we postulated 
that p21WAF1/CIP1 might mediate the caspase activation occurring during GTP-
depletion-induced apoptosis. To test this hypothesis, we utilized a specific inducer of 
p21WAF1/CIP1, mimosine, to mimic the MPA action. This is because mimosine is able to 
increase both p21WAF1/CIP1 mRNA and protein levels independent of p53 (Alpan and 
Pardee, 1996; Bissonnette and Hunting, 1998), an effect similar to that of MPA. It has 
been reported that this agent potently causes a reversible block of the cell cycle at late 
G1 phase and is frequently used to achieve cell synchronization at this stage (Alpan 
and Pardee, 1996; Ji et al., 1997; Krude, 1999). It was also found that mimosine can 
interfere with deoxyribonucleotide metabolism and inhibit DNA synthesis (Gilbert et 
al., 1995). We found that treatment of mimosine for 32 hrs significantly increased 
p21WAF1/CIP1 by 35% and 116% at 100 and 300 µM, respectively (Fig. 27A). 
Importantly, mimosine (300 µM), mimicking MPA effects, also simultaneously 
increased activity of caspase-2, -3 and -9 by 220%, 416% and 52%, respectively (Fig. 
27B). Furthermore, flow cytometric analysis revealed that mimosine inhibited the 
progress of cells from G1 to G2/M phase and promoted apoptosis as reflected by DNA  
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Fig. 27. Induction p21WAF1/CIP1 (A) and 
activation of caspases (B) by mimosine
treatment. HIT cells were treated with mimosine
in culture for 32 hrs. The levels of p21WAF1/CIP1 in 
cell lysates (20 µg protein extracts each) were 
determined by Western blotting and analyzed by 
computer-assisted densitometry. Caspase activity 
in cell homogenates were assessed by measuring 
the cleavage of the fluorogenic, specific substrates 
as described in details in the "Materials and 
Methods". Values are means of ± SEM of four (A) 
and three (B) independent experiments. * p<0.05 
and ** p<0.01 vs. control.
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fragmentation (an increase in sub-G1 fraction) (Fig. 28A). The number of apoptotic 
cells (sub-G1) was significantly increased by 1.3 and 5.6 folds (p<0.01) after treatment 
for 32 hrs with 100 and 300 mM mimosine, respectively (Fig. 28B). In addition, cells 
in S and G2/M phases were significantly reduced by 57% and 74% at 300 mM 
mimosine (Fig. 28B). Importantly, co-treatment of cells with the pan-caspase inhibitor 
Z-VAD-FMK (100 µM) could completely block mimosine-induced apoptosis and 
restore the arrest in cell cycle (Fig. 28A and 6B). However, mimosine-induced cell 
arrest and apoptosis was not dependent on GTP depletion, since co-treatment of cells 
with guanosine (500 µM) could not prevent the mimosine effects (data not shown). 
These data strongly indicate that p21WAF1/CIP1 may be the mediator acting as an 
upstream signal to activate caspases and in turn induce apoptosis during MPA 
treatment.  
It has been reported that p21WAF1/CIP1 is a substrate for executive caspases such as 
caspase-3 and this kind of degradation can be reversed by specific caspase inhibitors  
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Fig. 28. Blockade by a caspase inhibitor of 
mimosine-induced apoptosis. HIT cells 
seeded on 6-well plates were treated with 
mimosine in culture media for 32 hrs. Cells 
were stained with PI and subject to flow 
cytometric analysis of mimosine-induced 
subdiploid apoptotic cells. The cells whose 
DNA content was lower than G1 phase (sub-
G1) contained fragmented nuclei and were 
undergoing apoptosis. The graph is a typical 
representative of 4 independent experiments. 
The data in (B) show the statistical analysis 
of the mimosine effects on apoptosis and cell 
cycle. The results are expressed as 
percentages of total cells (10,000) evaluated 
by flow cytometry. * P<0.01 vs. individual 
mimosine treatment alone. 
 
(Gervais et al., 1998; Kwon et al., 2002). Similar phenomenon was also observed in 
our study. We found that the general caspase inhibitor Z-VAD-FMK, but not the 
caspase-2 inhibitor Z-VDVAD-FMK, enhanced the increment (+38%) of p21WAF1/CIP1 
due to MPA treatment (Fig. 29). This observation again suggests that p21WAF1/CIP1 
induction by GTP depletion is an event upstream of caspase activation during 
apoptosis, although activated caspases may exert a constraining effect on p21WAF1/CIP1 
levels. 
Fig. 29. Enhancement of MPA-induced 
p21WAF1/CIP1 increment by caspase
inhibitors. HIT cells were treated with MPA 
(3 µg/ml) in the presence or absence of a pan-
caspase inhibitor (Z-VAD-FMK) or a caspase-
2 inhibitor (Z-VDVAD-FMK) in culture for 32 
hrs. p21WAF1/CIP1 mass in cell lysates (20 µg 
protein extracts each) was determined and 
analyzed as described in the legend to Fig. 1. 
Values are means of ± SEM of thirteen 
independent experiments. *, p<0.05 vs. MPA 
treatment alone.
MPA         - +       +        +
Z-VAD         - - +    -
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3.3.4. Section summary 
This portion of work investigated the potential role of three cell cycle regulators (p53, 
p21WAF1/CIP1 and p27KIP1) in GTP-depletion induced apoptosis of β-cells, in particular 
their relationship with caspase activation. We observed that MPA treatment increased 
protein levels of p21WAF1/CIP1, an event which is well correlated with the time course of 
caspase activation. In contrast, p53 and p27KIP1 levels were decreased by MPA 
treatment. Thus the increase in p21WAF1/CIP1 mass and activation of caspases is p53-
independent. Moreover, treatment of β cells with mimosine, a p53-independent 
inducer of p21WAF1/CIP1, mimics MPA effects, resulting in p21WAF1/CIP1 increase, 
caspase activation and apoptosis. These data suggest that p21WAF1/CIP1 may act as an 
upstream signal to promote caspase activation and apoptosis in β cells during GTP-
depletion. 
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Chapter 4  
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4.1. The role of tTG in apoptosis induced by GTP depletion 
4.1.1. Evidence for association of tTG expression/activation with apoptosis 
The relationship between tTG and apoptosis has been broadly investigated in recent 
years, and it has been proposed that the enzyme may be a complex player of the 
crucial balance between survival and death (Fesus and Thomazy, 1988; Fesus, 1998; 
Melino and Piacentini, 1998; Autuori et al., 1998). Several lines of evidence point to a 
role of tTG in apoptosis. First, a wide range of signaling pathways can lead to the 
induction of apoptosis associated with increased tTG activity, such as in response to 
interleukins (Knight et al., 1993), TGF-β (Retter and Davies, 1998), nitric oxide 
(Bernassola et al., 1999), thapsigargin (increasing intracellular Ca2+ levels) (Furuya et 
al., 1994), and retinoids (Melino et al., 1997; Ritter and Davies, 1998). An 
augmentation of tTG expression (mRNA and/or protein), accompanied by cross-
linking of polypeptides, occurred during apoptosis (Fesus and Thomazy, 1988; Furuya 
et al., 1994; Melino et al., 1997; Ritter and Davies, 1998). An increase of tTG activity 
was also observed in isolated human islets undergoing loss of β-cells by apoptosis 
(Paraskevas et al., 2000). Thus tTG activation is often considered as a marker for 
apoptosis. Second, substantial knowledge of tTG in apoptosis has been accrued from 
studies using retinoic acid, a potent tTG inducer (Melino et al., 1997). This agent and 
its derivatives induced a marked increase (as high as 10-fold) of tTG expression and 
inhibited cell growth in G1 phase (Piacentini et al., 1993; Oliverio et al., 1999; Ozeki 
and Tsukamoto, 1999; Ou et al., 2000), often followed by apoptosis (Melino et al., 
1997; Oliverio et al., 1999; Ozeki and Tsukamoto, 1999; Ou et al., 2000) which could 
be blocked by inhibition of tTG activity with tTG inhibitors (Ou et al., 2000). It 
appeared that retinoids exerted the effects via their nuclear receptors acting on the tTG 
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promoter (Nagy et al., 1996) and might be mediated by the repression of the 
expression of bcl-2, c-fos and c-jun (Oliverio et al., 1999; Ozeki and Tsukamoto, 
1999), but not of p53 and p21WAF1/CIP1 (Ozeki and Tsukamoto, 1999), these proteins 
are important players in the apoptotic process. Third, experiments overexpressing tTG 
in fibroblasts and neuroblastoma cells provided further evidence for a role of tTG in 
the induction of apoptosis (Gentile et al., 1992; Melino et al., 1994). These cells 
displayed changes in morphology and adhesiveness characteristic of cells undergoing 
apoptosis as well as enhanced susceptibility to apoptotic stimuli (Gentile et al., 1992; 
Melino et al., 1994). Consistent with these findings, transfection of cells with tTG 
antisense markedly decreased both spontaneous and retinoic acid-induced apoptosis 
(Melino et al., 1994; Autuori et al., 1998; Oliverio et al., 1999). However, it is 
important to note that most of these studies involved massive over-expression of tTG 
levels and/or use of stimuli such as retinoids which do not work through changes in 
GTP, as was the subject of our study.  
4.1.2. Increase of tTG activity by GTP depletion per se but not by its up-
expression in HIT cells 
Cell growth is affected by both accumulation (Sidi and Mitchell, 1984) and depletion 
(Metz and Kowluru, 1999; Cohn et al., 1999; Allison and Eugui, 2000; Metz et al., 
2001) of GNs. Under the latter condition, cell growth is inhibited, with drastic 
reduction in DNA synthesis and alternations in RNA and protein synthesis. We have 
previously demonstrated that MPA and mizoribine, two structurally-dissimilar 
IMPDH inhibitors, induce apoptosis of insulin-secreting cells (Li et al., 1998). The 
current studies investigated the role of tTG in apoptosis using our unique system in 
which the death of HIT cells is induced by MPA. We hypothesized that since tTG is 
GTP-dependent (Smethurst and Griffin, 1996; Melino and Piacentini, 1998; Zhang et 
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al., 1998) and has been implicated in at least the morphological changes of apoptosis 
(Gentile et al., 1992; Trejo-Skalli et al., 1995; Melino and Piacentini, 1998), it would 
be a logical candidate to mediate at least a part of the cell death induced by GTP-
deficiency. Although 7 transglutaminases have been identified (Aeschlimann et al., 
1998), the increase in transamidating activity in MPA-treated β-cells observed in our 
study appeared due to the activation of GTP-sensitive tTG for two reasons. First, only 
tTG and epidermal transglutaminase (TG3) are sensitive to GTP; the increased 
transamidation could be completely prevented by the provision of guanosine (cf. Fig. 
9B) which restores the cellular GTP levels. Second, all other transglutaminases except 
tTG are distributed in specific tissues (Aeschlimann et al., 1998). Our results for the 
first time revealed the presence of tTG in the β-cells by Western-blotting.  
We observed increased in situ activity of the enzyme after inhibition of GTP synthesis. 
In contrast to the observations of increased tTG expression in other studies (Furuya et 
al., 1994; Melino et al., 1997; Ritter and Davies, 1998), however, this increment of 
tTG activity by MPA was not associated with an augmented expression of tTG protein 
(rather even with reduced mass at late treatment time periods) in our study. This 
phenomenon indicated that MPA altered tTG activity by lowering intracellular GTP 
level and not by increasing its synthesis, since tTG activity is negatively regulated by 
intracellular GTP levels (Smethurst and Griffin, 1996; Melino and Piacentini, 1998; 
Zhang et al., 1998). This notion was further supported by our experiments using 
guanosine which, by restoring GNs to normal levels (Metz et al., 1992; Meredith et al., 
1997; Li et al., 2000), blocked the increase of tTG activity and prevented HIT cells 
from apoptosis due to MPA. An increase of tTG activity during apoptosis but 
unaccompanied by amplified expression of tTG has also been observed in other 
studies (Korner et al., 1993; Holmes and Haynes, 1996). 
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tTG acts not only intracellularly but also can be released by externalization to 
extracellular space there tTG facilitates the assembly and remodeling of extracellular 
matrices and promotes cell adhesion (Gaudry et al., 1999a; Gaudry et al., 1999b; 
Verderio et al., 1999; Balklava et al., 2002; Rosenthal et al., 2003; Gross et al., 2003). 
Though not directly examined, such phenomena might occur also in our MPA-treated 
HIT cells, which could account for the reduction of tTG mass at late treatment time 
periods.  
4.1.3. tTG activation is an epiphenomenon during MPA-induced apoptosis of HIT 
cells 
Importantly, we observed that the time-course of the increase of in situ tTG activity 
was paralleled with the induction of programmed cell death. Consequently, whether 
tTG is an upstream effector in the induction of GN-depletion induced apoptosis was 
examined by using its inhibitors. It has been reported that tTG inhibitors block 
apoptosis induced both by retinoic acid (Ou et al., 2000) and by expressing truncated 
DRPLA (dentatorubral-pallidoluysian atrophy) protein (Igarashi et al., 1998). In our 
study, two specific tTG inhibitors (MDC or putrescine) (Tsai et al., 1998) reduced 
MPA-evoked tTG activity by ~43%. However, the inhibitors were barely able to 
relieve cell death caused by MPA treatment. In addition, tTG activity is also regulated 
by intracellular Ca2+ levels (Smethurst and Griffin, 1996; Melino and Piacentini, 1998; 
Zhang et al., 1998). Although the enzyme is not active at Ca2+ levels normally detected 
in viable cells (<1 µM) (Folk, 1980), the apoptosis-associated rise in cellular Ca2+ 
concentrations is sufficient to activate it (Fau et al., 1997). We have previously 
observed that even 6-hr MPA treatment raised resting intracellular Ca2+ levels by 20% 
in HIT cells (Li et al., 2000). It is thus very likely that higher Ca2+ levels would be 
reached in these cells after longer MPA treatment, which may contribute to tTG 
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activation. Therefore, a Ca2+ chelator was used to lower extracellular Ca2+ to 80-120 
nM (much lower than 1 µM that activates tTG). This maneuver could almost abolish 
the increased tTG activity due to GN depletion by MPA treatment, but was still only 
capable of partially protecting the cells from death. Thus these experiments inhibiting 
tTG did not clearly reveal a biologically-significant role for this enzyme as an 
“initiator” of cell death induced by GTP-depletion. In a study by Zhang et al., MDC 
prevented the increase in the cross-linked envelopes caused by tTG activation, but 
failed to inhibit DNA fragmentation due to interferon-β (Zhang et al., 1999a). 
Therefore, it seems that the major role of tTG in apoptosis is to function as a 
downstream effector in the late phase of apoptosis (Fesus, 1998; Melino and 
Piacentini, 1998). By catalyzing the Ca2+-dependent formation of an insoluble protein 
scaffold from stable cross-links between proteins during apoptosis (Fesus and 
Thomazy, 1988; Fesus, 1998; Melino and Piacentini, 1998; Autuori et al., 1998), tTG 
could maintain the contents of the dying cells before their clearance by phagocytosis, 
and thus prevent the non-specific leakage of harmful intracellular components (e.g. 
lysosomal enzymes, nucleic acids, etc.) and consequently inflammatory responses 
(Melino and Piacentini, 1998). We found that 48-h exposure to MPA caused a marked 
increase of LDH release. However, neither a combination of two tTG inhibitors (MDC 
and putrescine) nor lowing Ca2+ by EGTA affected the MPA-induced LDH release. 
These findings suggest that tTG is also unlikely to be involved in the terminal release 
of large molecular compounds from the apoptotic cell. Our findings indicate that 
although an increase of tTG activity may accompany apoptosis, the activation of this 
enzyme may be not essentially required for the induction or execution of at least a 
significant number of the changes seen during apoptosis. 
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4.1.4. Role of tTG in GTP depletion-induced apoptosis of HIT cells 
The possible role of tTG in maintaining cell integrity for apoptotic cells to avoid the 
release of cellular components leading to inflammation was proposed but is not well 
defined. The liver cells undergoing apoptosis induced extensive cross-linking of 
cellular proteins resulting in the formation of SDS-insoluble shells (similar to 
cornified envelopes of epidermis) in the so-called "apoptotic bodies" that contain 
oligonucleosomal fragments (Fesus et al., 1989). The insolubility of these apoptotic 
bodies was evoked by protein cross-linking bonds formed by tTG (Fesus et al., 1989). 
A later study observed that an increase of tTG activity in hepatocytes was paralleled 
by formation of SDS-insoluble apoptotic bodies (Piacentini et al., 1991). In addition, 
intense tTG immunostaining is also found in the apoptotic bodies present inside 
phagosomes within the cytoplasm of neighboring cells (Piacentini et al., 1991). Thus 
cross-linking proteins by tTG plays a role in the formation of apoptotic bodies ready to 
be cleaned by the engulfing cells. Many substrates of tTG are cytoskeletal proteins and 
some are nuclear proteins such as Rb (Melino and Piacentini, 1998), but there is no 
evidence that LDH is a tTG substrate. Published studies did not reveal a relationship 
between LDH release and tTG activity in apoptotic cells in which the tTG was either 
knocked out or highly expressed (De, V and Melino, 2001; Tucholski and Johnson, 
2002). In one study, however, the number of cross-linked apoptotic bodies was 
significantly reduced in the tTG knockout cells (De,Laurenzi and Melino, 2001). The 
postulated role of tTG in the maintenance of cell integrity may occur in a critical 
period during the apoptotic process, i.e. DNA fragmentation and formation of 
apoptotic bodies before being engulfed by neighboring cells. In MPA-treated HIT 
cells, DNA fragmentation occurred after 24-h treatment (Li et al., 1998). Taken 
together, the data suggest that while tTG is unlikely to mediate cytoplasmic leakage in 
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terminally apoptotic or necrotic cells (at least of large molecular weight molecules 
such as LDH), cross-linking of proteins by tTG may well play an important role in the 
morphological changes during programmed cell death. For the latter effect, 
cytoskeletal proteins (actin, microtubules and intermediate filaments) may be 
implicated since they act not only as the anchorage sites but also the substrates for tTG 
in cells undergoing apoptosis (Trejo-Skalli et al., 1995; Melino and Piacentini, 1998; 
Piredda et al., 1999). We indeed observed that the alterations of HIT cell morphology 
which accompanied tTG activation during MPA treatment were blocked by guanosine 
and partially relieved by tTG inhibitors. We emphasize however, that we cannot 
exclude the possibilities that other roles for tTG might have been unmasked if we had 
been able to inhibit it completely, or if we had studied different inducers of apoptotic 
cell death. 
4.1.5. Relationship between tTG and caspases 
It is now known that caspases play an essential role in both initiation and execution of 
apoptosis (Green and Reed, 1998; Budihardjo et al., 1999). Many of tTG-targeted 
proteins are also substrates of caspases (Autuori et al., 1998) and thus there may exist 
a relationship between tTG and caspases. In our study, tTG activation by GTP-
depletion was not affected when a pan-caspase inhibitor blocked activity of all 
caspases (Huo et al., 2002). More importantly, our data indicated that the rise in tTG 
activity was not merely secondary to the apoptosis induced by GTP depletion, since 
the pan-caspase inhibitor prevented the cell from death but did not suppress the 
augmented tTG activity. Alternatively, this observation cannot completely rule out the 
possibility that tTG activation is an upstream event of caspase activation in GTP-
depleted cells; the unavailability of more potent tTG inhibitors impedes the assessment 
of this possibility. However, the morphological changes evoked by GTP-depletion 
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could not be completely reversed by the caspase inhibitor, allowing for the possibility 
of an additional important role of tTG in this aspect. This concept was further 
substantiated by the observation that tTG inhibitors were able to partially prevent 
MPA-induced changes in cell morphology, corresponding to the partial suppression of 
the enhanced tTG activity under such conditions. Interestingly, tTG is a caspase-3 
substrate and is cleaved during apoptosis in lymphoid cells (Fabbi et al., 1999). 
Cleavage of tTG causes loss of its cross-linking function, and this event was regarded 
as a valuable biochemical marker of caspase 3 activation during the late execution 
phase of apoptosis. This may explain our observation of reduction of tTG mass in HIT 
cells at late MPA treatment (48 hrs) following activation of caspases. Alternatively, 
the reduction of tTG mass might be due to the activation of other proteases, since it 
has been reported that, in neuroblastoma SH-SY5Y cells, depletion of GTP increases 
tTG degradation by calpain after elevation of intracellular Ca2+ levels (Zhang et al., 
1998), a phenomenon perhaps also occurring in our HIT cells (Li et al., 2000).  
In conclusion, tTG may play a role as a downstream regulator in GN-depletion 
induced apoptosis in HIT cells, but this role seems to be principally involved to the 
terminal morphological changes. Interestingly, it has been reported that an increase of 
tTG activity was not observed during apoptosis under some circumstances, such as by 
treatment with dexamethasone (Johnson et al., 1998), peroxinitrate (Virag and Szabo, 
2000), and by Fas-receptor stimulation (Szondy et al., 1997). Moreover, apoptosis 
induced by various agents were not affected in tTG “knock-out” cells (De, V and 
Melino, 2001). These studies, in conjunction with the current ones, suggest that the 
hypothesis that tTG is a universally crucial component of the main pathway of the 
early apoptotic programs remains to be substantiated.  
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4.2. Caspase activation in β-cell apoptosis induced by GTP depletion 
4.2.1. Activation of multiple caspases in MPA-induced apoptosis of HIT cells  
Our data strongly suggest that HIT cell apoptosis due to GN-depletion was mediated 
by activation of at least two initiator caspases (caspase-2 and caspase-9) and at least 
one effector caspase (caspase-3). In addition, caspase-3 activation occurred later than 
caspase-2 and a specific caspase-2 inhibitor also blocked caspase-3 activation, 
indicating that the latter is activated subsequent to the former. Caspase-3 is a 
downstream effector directly killing cells in some circumstances (Banki et al., 1999; 
Soane et al., 1999), but there is increasing evidence that caspase-3 inhibition fails to 
block apoptosis in other systems (Tepper et al., 1997; Bras et al., 1999). In our study, a 
caspase-3 inhibitor failed to prevent the β-cell from death induced by GTP-depletion; 
however, it exerted some protective effect on DNA reduction which may suggest some 
role in the latter process. This also suggests that other effector caspases play important 
roles, along with caspase-3, in the final execution of cell death. 
4.2.2. Caspase-2 activation is prior to cytochrome c release and caspase-9 
activation 
We found that caspase-2 in HIT cells was mainly localized in cytosol and only a small 
portion was detected in mitochondria-rich fraction. It has been proposed that caspase- 
2 and -9 zymogens and cytochrome c essentially localized in mitochondria may be 
released and become activated, eventually triggering of apoptosis (Green and Reed, 
1998; Li et al., 1997b; Ito et al., 1999; Banki et al., 1999; Susin et al., 1999a). Thus the 
integrity of mitochondria may be critical for subcellular redistribution and activation 
of these caspases. In this study, we could not find detectable changes of caspase-2 
content in mitochondria after GN-depletion, suggesting that the activated caspase-2 is 
not mainly derived from mitochondria. Although we did observe the leakage of 
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cytochrome c from mitochondria and modest activation of caspase-9 (indicating a 
damage of the organelles) occurred in GN-depleted β-cells, these events took place 
later than the increase of caspase-2 activity. In addition, a caspase-2 inhibitor was able 
to suppress the activation of both caspase-2 and caspase-9. All these results suggest 
that cytochrome c release and activation of caspase-9 are delayed or secondary 
phenomenon and the damage to mitochondria might not be the essential event in the 
triggering of apoptosis induced by sustained GN depletion. 
4.2.3. Activation of caspase-2 mediates β-cell apoptosis due to GN-depletion 
Caspase-2 is involved in the apoptosis under a variety of conditions. It is activated 
during cell death induced by TNFR in B-lymphocytes and other cells (Thome et al., 
1998; Shearwin-Whyatt et al., 2000), but the major mediator of TNFR is caspase-8 as 
the deletion of RAIDD (caspase-2 adaptor) failed to block TNF-induced apoptosis 
(Duan and Dixit, 1997). Caspase-2 activation is also required for the apoptosis induced 
by withdrawal of trophic support from PC cells and sympathetic neurons (Stefanis et 
al., 1999) and caspase-3-like activity is not required in this paradigm. TGFβ-evoked 
apoptosis of a variety of cells also involves caspase-2 activation (Choi et al., 1998). 
Thus it is highly possible that the antecedent blockade of mitogenesis (Fig. 16A and 
Table 5) subsequently induces apoptosis (Fig. 16B, C) to prevent accumulation of 
DNA-aberrant cells in G1/S phases. It is interesting to note that caspase-2, similar to 
its effect in GN-depletion-elicited HIT cell death, plays a major role in apoptosis in B-
lymphocytes induced by B cell receptor (BCR) cross-linking (Chen et al., 1999). In the 
latter system, caspase-2 was activated early and markedly while caspase-9 activity was 
moderately enhanced without the involvement of caspase-8. In addition, the cell death 
could be prevented by pan-caspase inhibitors or specific caspase-2 inhibitor, 
resembling the findings in GN-depletion induced apoptosis of HIT cells. Thus 
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caspase-2 activation may represent another major class of apoptotic pathways distinct 
from that mediated by caspase-8 and caspase-9 (Kumar, 1999; Earnshaw et al., 1999). 
4.2.4. Possible mechanism for caspase-2 activation in β-cell by GN-depletion 
How does GN depletion activate caspase-2 in β-cells? Although it might involve the 
inhibition of primer RNA biosynthesis (Catapano et al., 1995), reductions in mitogenic 
competence, and/or the interference with the function of some small G-proteins 
(Kowluru et al., 1996; Li et al., 1998), the exact nature of the upstream mediators 
leading to the observed activation of caspase-2 is unclear. It has been proposed that 
RAIDD may be an upstream regulator of caspase-2 since an interaction between the 
two proteins occurs both in the cell and in cell-free system (Duan and Dixit, 1997; 
Shearwin-Whyatt et al., 2000). Endogenous RAIDD is mainly localized in the 
cytoplasm and to some extent in the nucleus, where its interaction with caspase-2 may 
occur (Shearwin-Whyatt et al., 2000). We also found that RAIDD interacts with 
caspase-2 in HIT cells, as assessed by immuno-precipitation. It appeared this 
interaction was slightly reduced by GN-depletion. What importance of this change to 
GN-depletion induced apoptosis is unclear in the moment since there is no study 
which reported an alteration of RAIDD-caspase-2 interaction during apoptosis. 
Our other preliminary studies may shed some light on the mechanism underlying 
caspase-2 activation by GN-depletion. It is known that the molecules involved in the 
regulation of cyclin-dependent kinases (CDKs) (Matsumoto et al., 1999), such as p53 
and p21WAF1/CIP1, play an important role in the control of cell survival and death 
(Jayaram et al., 1999; Zhang et al., 1999b). p53 is a tumor suppressor that regulates 
p21WAF1/CIP1 and its expression is often increased in apoptotic cells (Wu et al., 1998; 
Zhang et al., 1999b). Cdk4 is particularly important for islet β-cell growth and post-
natal survival (Rane et al., 1999). Induction of p21WAF1/CIP1 is observed in the islets 
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under growth arrest and death due to exposure to oxygen radicals (Kaneto et al., 
1999a). Similar increases in p21WAF1/CIP1 and also p53 occur in amylin-induced β-cell 
death (Zhang et al., 1999b). It is of particular interest that p53 may regulate IMPDH 
(and vice versa) (Sherley, 1991), the key enzyme in GTP biosynthesis which is 
targeted by MPA. Nonetheless, p53 seems unlikely to play a major role in GN-
depletion induced apoptosis as its mass was reduced after MPA treatment (Fig. 24). 
Interestingly, however, our results (Fig. 23) indicated that p21WAF1/CIP1 was up-
regulated in close parallel with caspase-2 activation, suggesting that p21WAF1/CIP1 
might be involved in the initiation of cell death due to GN depletion. Moreover, the 
increase in p21WAF1/CIP1 during GN-depletion could not be blocked by caspase 
inhibitors which prevented β-cells from death, suggesting that p21WAF1/CIP1 might be 
an upstream signal for caspase-2 activation (see more discussions later in the Section 
4.3). 
4.2.5. Involvement of caspases in β-cell death caused by harsh challenges 
Both clinical and experimental studies indicate that a failure of islet β-cell function, 
arrest of cell growth and promotion of cell death by apoptosis occur during challenge 
with cytokines, glucose toxicity or lipo-toxicity (Shimabukuro et al., 1998; Pick et al., 
1998; Kay et al., 2000). Cytokines such as IL-1β, TNF and interferon-γ induce damage 
and induce β-cell death via Fas and TNFR (Iwahashi et al., 1996; Delaney et al., 1997; 
Stephens et al., 1999). Similar apoptotic effects on β-cells are also seen subsequent to 
the stimulation of amyloid (Zhang et al., 1999b) or free radicals such as nitric oxide 
generated from streptozotocin (Kaneto et al., 1999b). However, the information on 
caspases in the death of islet β-cells occurring in the above circumstances is very 
fragmentary. Our unpublished data indicate that caspase-2 may be not the critical 
protease in all forms of programmed cell death, since the caspase-2 inhibitor (Z-
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VDVAD-FMK) could not prevent the apoptotic death of HIT cells induced by 
streptozotocin and only partially (by ~30%) reversed cytokine (IL-1β plus TNFα)-
induced HIT cell death. It has been reported that IL-1β lowered GTP by ~60% in islet 
β-dells (Meredith et al., 1996). Other studies reported the activation of caspase-1 and -
3 by cytokines in β-cells (Stephens et al., 1999; Karlsen et al., 2000). These 
observations suggest again that caspase-2 activation may play a specific, critical role 
in the apoptosis induced by GN-depletion with MPA, due to impairment of 
mitogenesis. Little is known about the role of caspases in β-cell apoptosis caused by 
glucose toxicity and lipid-toxicity. Our preliminary results indicated that high 
concentrations of free fatty acid increased the activity of both caspase-2 and caspase-3 
in insulin-secreting INS-1 cells (data not shown). The present study on β-cell growth 
and death during GTP-depletion may enrich our knowledge in this aspect. 
In conclusion, this is the first study reporting that multiple caspases (including at least 
caspase-2, -3, and -9) were activated and the release of mitochondrial cytochrome c 
occurred during apoptosis of β-cells induced by GTP depletion with MPA. 
Importantly, caspase-2 like protease(s) was activated earlier and more dramatically 
than other caspases. Furthermore, GTP-depletion induced apoptosis and caspase 
activation were blocked by a pan-caspase inhibitor and, significantly, protected by a 
specific caspase-2 inhibitor as well, pointing a major role of the latter in the initiation 
of apoptotic death of insulin-secreting HIT cells. Thus our study revealed a novel, 
caspase-2 mediated form of apoptosis that may be consequent to impaired mitogenesis 
as demonstrated by flow cytometry in the current study and by thymidine/BrdU 
incorporation previously (Li et al., 1998; Metz et al., 2001). 
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4.3. Role of cell cycle regulators in β-cell apoptosis induced by GTP 
depletion 
We have observed that specific GTP depletion by MPA restrained mitogenesis of 
insulin-secreting cells by reducing their progression from G1 phase into S and G2/M 
phases, resulting in apoptosis mediated by activation of caspases (Li et al., 1998; Huo 
et al., 2002). We further defined the linkage between cell cycle arrest and the induction 
of apoptosis induced by MPA treatment in HIT cells. Our data indicate that MPA 
induced p21WAF1/CIP1 expression which was closely correlated with activation of 
caspases. Furthermore, a specific p21WAF1/CIP1 inducer, mimosine, could mimic the 
MPA effects on activation of caspases resulting in apoptosis (but in GTP-independent 
manner). To our knowledge, this is the first study systematically investigating 
p21WAF1/CIP1 and establishing its relationship with caspase activation during apoptosis 
induced by GTP depletion.  
4.3.1. Close relationship between p21WAF1/CIP1 and caspase activation in β-cells 
It is well known that CKIs are able to inhibit cell proliferation by negatively affecting 
cyclin-CDK complexes. By doing so, p21WAF1/CIP1 and p27KIP1 regulate the progression 
through G1 and the G1/S transition (Toyoshima and Hunter, 1994; Polyak et al., 
1994). Since depletion of cellular GNs by MPA inhibits cell proliferation and arrests 
cell cycle in G1 phase (Mitchell et al., 1993; Laliberte et al., 1998; Huo et al., 2002), it 
is possible that MPA may alter p21WAF1/CIP1 and p27KIP1 expression to achieve this 
effect. Only one study has mentioned the induction of p21WAF1/CIP1 by MPA (1 µM) in 
T lymphocytes and this effect occurred at 42-h, but not 24-h, treatment with MPA 
(Laliberte et al., 1998). In the present study, we found that depletion of GNs by MPA 
treatment caused increases of p21WAF1/CIP1 following a time-course which was in 
parallel with the activation of several caspases (cf. Fig. 23), suggesting a close 
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relationship between the two events. Importantly, significant accumulation of 
p21WAF1/CIP1 and activation of caspases were observed as early as 16 hrs of MPA 
treatment and thus preceded the occurrence of apparent apoptosis (at 24 hrs) of HIT 
cells (Li et al., 1998; Huo et al., 2002).  
To further examine the possible sequence of observed caspase activation and 
p21WAF1/CIP1 accumulation, we used mimosine, a well-known p21WAF1/CIP1 inducer, to 
study its effects on the two events. By increasing p21WAF1/CIP1, this compound has been 
found to be a potent, reversible blocker synchronizing cells in late G1 phase (Alpan 
and Pardee, 1996; Ji et al., 1997; Krude, 1999). Mimosine increased both p21WAF1/CIP1 
mRNA and protein levels bypassing the requirement for transcriptional activation by 
p53 (Alpan and Pardee, 1996; Bissonnette and Hunting, 1998). However, there is no 
study reporting its effect on caspases and apoptosis directly. In the current study, we 
found that mimosine had effects similar to those of MPA in increasing p21WAF1/CIP1 
and inducing activation of same types of caspases (Fig. 27). Moreover, under these 
conditions, mimosine suppressed cell cycle and promoted caspase-mediated apoptotic 
death of HIT cells, the same effects observed after MPA treatment (Fig. 16). Although 
it has been reported that mimosine inhibits deoxyribonucleotide metabolism (Gilbert et 
al., 1995), we found that its effects on cell arrest and apoptosis are not due to a 
depletion of GTP. Our experiments using caspase inhibition further uncovered the 
relationship between p21WAF1/CIP1 and caspase activation. When caspases were 
suppressed by a pan-caspase inhibitor, p21WAF1/CIP1 mass was even modestly enhanced 
during MPA treatment (Fig. 29), indicating that GN depletion can induce p21WAF1/CIP1 
without caspase activation, in other word, prior to caspase activation. These 
observations strongly suggest p21WAF1/CIP1 may act as an upstream signal to activate 
caspases. Therefore, we can infer that sustained GTP-depletion significantly increased 
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p21WAF1/CIP1 accumulation which triggered a cascade of activation of caspases leading 
to apoptosis since GTP repletion reversed these effects.  
4.3.2 Activation of caspase(s) and p21WAF1/CIP1 degradation  
The observation of enhanced p21WAF1/CIP1 accumulation in the presence of a pan-
caspase inhibitor also implies that p21WAF1/CIP1 may be degraded by activated caspases. 
Indeed, there is evidence that p21WAF1/CIP1 may be a substrate of effector caspases in 
the late stage of apoptosis (Chai et al., 2000; Kwon et al., 2002). The significance of 
this phenomenon, however, is unclear. It might be a negative feedback mechanism 
whereby the cell protects itself from damage by shutting off the upstream signals. 
4.3.3. Induction of p53-independent p21WAF1/CIP1 increment by MPA 
Ample evidence demonstrated that induction of p21WAF1/CIP1 can be achieved by either 
p53-dependent (El Deiry et al., 1993; El Deiry et al., 1994) or -independent pathways 
(Agarwal et al., 1995; Alpan and Pardee, 1996). In lymphocytes 24-h treatment with 
MPA (1 µM) resulted in a very low level of p53 expression (Laliberte et al., 1998). In 
our study, the p21WAF1/CIP1 induction was apparently not mediated by p53, since the 
latter was progressively reduced by MPA treatment in both time- and dose-dependent 
manner. Thus p53 may not be an important mediator for MPA-induced apoptosis. 
IMPDH is a key enzyme for biosynthesis of GNs and its gene expression is regulated 
inversely by a posttranscriptional nuclear event in response to fluctuations in the 
intracellular level of GNs (Glesne et al., 1991). As a specific inhibitor of IMPDH, 
MPA diminished GNs levels and, therefore increased levels of IMPDH mRNA and 
amounts of the enzyme (Glesne et al., 1991; Metz et al., 2001). In addition, IMPDH 
activity and its protein and mRNA levels could be down-regulated by p53 and thus 
this enzyme (or the resultant changes in cellular levels of GNs) might play an 
important role in mediating p53-dependent suppression of cell growth (Sherley, 1991; 
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Liu et al., 1998b; Jayaram et al., 1999; Yalowitz and Jayaram, 2000). The reciprocal 
effect of IMPDH on p53 has not been reported. However, our findings that p53 was 
decreased by GTP depletion [which would increase IMPDH expression (Metz et al., 
2001)] suggested such a possible consequence. This notion was further supported by 
the results obtained using caspase inhibitors. Under these conditions, caspase 
activation and apoptosis due to MPA were blocked while GNs remained depleted 
(Huo et al., 2002) and the effect of reducing p53 was not affected (cf. Fig. 26A). Only 
restoration of GNs by guanosine was able to prevent p53 reduction (cf. Fig. 24B). 
Thus we can conclude that p53 decrement in HIT cell during MPA-induced apoptosis 
is attributable to GTP depletion. Alternatively, the reduction of p53 mass may be due 
to the degradation by some unknown proteases activated by GN depletion. 
4.3.4. p27KIP1 degradation by MPA treatment 
Little information on the effect of GN on p27KIP1 is available. One study reported that 
MPA prevented the IL-2-induced elimination of p27KIP1 and resulted in the retention 
of high levels of p27KIP1 in IL-2/leucoagglutinin-treated T cells (Laliberte et al., 1998). 
Our data revealed that MPA-induced arrest of HIT cells may not be mediated by 
p27KIP1 since the mass of this CKI was actually reduced by MPA in a dose- and time-
dependent manner. In addition, p27KIP1 was not a substrate of caspases activated by 
GN depletion, since the reduction of p27KIP1 was not reversed by caspase inhibitors, 
suggesting an effect possibly related to GN depletion directly. Whether this reduction 
was due to decreased expression or to increased degradation of the protein is unclear. 
The level of p27KIP1 is regulated in several ways (Slingerland and Pagano, 2000), the 
precise biochemical link between GTP depletion and p27KIP1 reduction in islet β-cells 
remains to be clarified in further study. Interestingly, in this study we found that both 
p53 and p27KIP1 were decreased (though the latter was more sensitive) following MPA 
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treatment; but it is not known whether any relationship exists between the two events 
based on the data from this study and the studies reported in the literature. 
4.3.5. Cell cycle and apoptosis in β-cells 
Cell cycle molecules play important roles in islet β-cell growth and death and the 
development of diabetes. It has been found that Cdk4 (which forms a complex with 
cyclin D1 and is required for the progression of cell cycle from G1 to S phase) is 
essential for islet β-cell growth and postnatal survival and that the loss of its 
expression causes insulin-deficient diabetes in laboratory models (Rane et al., 1999; 
Tsutsui et al., 1999). Degeneration of pancreatic islets by apoptosis also occurs in the 
Cdk4 knockout mice after birth (Tsutsui et al., 1999). In addition, there is evidence 
that induction of p21WAF1/CIP1 expression is involved in islet β-cell death caused by 
oxidative stress (Kaneto et al., 1999a), which may contribute to glucose toxicity. In 
another study, enhanced expression of p53 and p21WAF1/CIP1 occurred in amylin-
induced apoptosis of insulin-secreting cells (Zhang et al., 1999b). Our findings in this 
study and the results by others (Kaneto et al., 1999a; Zhang et al., 1999b) have 
suggested that p21WAF1/CIP1 may play an important role of in the regulation of islet β-
cell apoptosis (Fig. 30). 
In conclusion, our results demonstrated that depletion of GNs in HIT cells induced 
p53-independent up-expression of p21WAF1/CIP1, an effect closely correlated with the 
time-couse of activation of caspases and induction of apoptosis. In addition, an 
increase of p21WAF1/CIP1 was still observed when caspase activation was suppressed.  
Both p53 and p27Kip1 seem not to play an important role in the apoptosis induced by  
MPA treatment, since they were degraded during the process. A selective inducer of 
p21WAF1/CIP1 mimicked the MPA effects, causing caspase activation and apoptosis 
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which could be blocked by a pan-caspase inhibitor.  These observations suggest that 
an induction of p21WAF1/CIP1 may mediate the arrest of cell cycle, activation of 
caspases and, in turn, apoptotic cell death of insulin-secreting cells. 
Fig. 31. Schematic diagram for a role of 
p21WAF1/CIP1 in β-cell growth and death. 
Inhibition of IMPDH by MPA causes 
GTP depletion resulting in p53-
independent induction of p21WAF1/CIP1. 
Oxidative stress due to glucose toxicity 
and other hostile challenges may also 
induce p21WAF1/CIP1. Elevation of 
p21WAF1/CIP1 may inhibit CDKs such as 
CDK4 which is essential for b-cell 
survival. This will suppress mitogenesis
which in turn lead to caspase activation 
and triggers apoptosis as demonstrated in 
the present study. Amylin may induce 
apoptosis of b-cells by enhancing 
expression of p21WAF1/CIP1 Mimosine
mimics MPA effects to increase 
p21WAF1/CIP1 and promote apoptosis which 
is blocked by a pan-caspase inhibitor.












4.4. Future work 
The results from this work enriched our understanding of the molecular mechanism 
whereby GTP depletion induces apoptosis of islet β-cells. We found that activation of 
caspase-2 subsequent to inhibition of mitogenesis plays a critical role in this scenario. 
Furthermore, our study on cell cycle regulators suggested that p21WAF1/CIP1 
accumulation may be an upstream signal which leads to cell cycle arrest, caspase 
activation and eventually apoptosis in our experimental system. However, several 
important issues (below) remain to be addressed for the thorough elucidation of how 
GTP depletion causes apoptotic cell death.  
1). We have found that GTP depletion resulted in an up-regulation of p21WAF1/CIP1, but 
not p53 and p27KIP1; these cell cycle regulators are critical checkpoint target 
proteins which may determine either cell growth or cell cycle arrest to apoptosis. 
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Our notion that an up-regulation of p21WAF1/CIP1 is closely associated with caspase 
activation during GTP depletion induced apoptosis of β-cells, however, is based on 
the indirect observations, i.e. by comparing the time course of the two events and 
by using a p21WAF1/CIP1 inducer. Therefore, more direct evidence is required for 
ascertaining the existence of such causal relationship between p21WAF1/CIP1 and 
caspase activation during GTP depletion. One means to achieve this would be to 
selectively suppress or knock down p21WAF1/CIP1 and then to examine MPA-
induced caspase activation and apoptosis. Unfortunately, no p21WAF1/CIP1 inhibitor 
is available. However, using molecular biology tools (transfection of cells with 
either antisense oligonucleotides or siRNA of p21WAF1/CIP1) to explore this 
interesting hypothesis seems to be feasible; such experiments are currently in 
progress. 
2).  MPA treatment can lower cellular GTP to levels which would impede the function 
of GTP-binding proteins (Kowluru et al., 2002). Our earlier study revealed that 
interference with small G-proteins by blockade of their isoprenylation is able to 
induce β-cell apoptosis. In addition, inactivation of the Rho subfamily of G-
proteins by Clostridium difficile toxin B potentiates MPA-induced β-cell apoptosis 
(Li et al., 1998). Therefore,  intervention of a small G-protein may mediate 
between GTP depletion and the events initiating cell death. However, it appears 
that Rac1 (a member of Rho subfamily proteins) is not involved in this process, 
since transfection of either a dominant-negative or -positive Rac1 mutant in β-cells 
did not alter MPA-induced apoptosis (data not shown). Thus, other G-proteins, e.g. 
Cdc42 and Ras (Kowluru and Morgan, 2002), should be targeted.  
3).  At the late stage of apoptosis, activation of executive caspases plays an essential 
role in the degradation of critical proteins, leading to cell destruction. Although 
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caspase-3 is a player of such function in many circumstances, a specific inhibitor 
of caspase-3 could not prevent MPA-induced apoptosis of HIT cells in the current 
study. Therefore, other executive caspases should be investigated. Moreover, a 
possibility of the participation of other proteolytic enzymes in the execution of cell 
death in our experimental system, such as calpains (similar to caspases, also a 
family of cysteine proteases) (Chan and Mattson, 1999), granzymes (a family of 
serine proteases) (Trapani, 2001), and even the ubiquitin-proteasome (Almond and 
Cohen, 2002) is also required for investigation in the future study.  
4).  In the study of the role of tTG in GTP depletion induced apoptosis of β-cells, we 
observed a close correlation between the increase of tTG activity and the induction 
of apoptosis. In addition, there is evidence that the former might precede the latter. 
However, two widely-used tTG inhibitors failed to rescue the cells from death, 
which might be due to the fact that the inhibitors were only able to suppress part of 
the elevated tTG activity. Although lowering Ca2+ was capable of blocking most of 
the augmented tTG activity due to GTP depletion, this maneuver might have other 
non-selective effects (e.g. cell morphology) which could complicate MPA action. 
Therefore, finding a new way to complete remove tTG activity is required to make 
a solid conclusion about the role of tTG in apoptosis of β-cells induced by GTP 
depletion. This goal is probably achievable by knocking down tTG through 
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